@NP	NT-3 expression from engineered olfactory ensheathing glia	1
@NP	NT-3 expression	1
@NP	engineered olfactory ensheathing glia	22
@NP	spinal sparing and regeneration Marc J.	69
@NP	spinal sparing	69
@NP	regeneration Marc J.	88
@NP	Ruitenberg ,1,2,3 Dane B.	110
@NP	Ruitenberg	110
@NP	,1,2,3 Dane	120
@NP	B.	132
@NP	Levison ,1 Seok Voon Lee ,1 Joost Verhaagen ,3 Alan R.	135
@NP	Levison ,1 Seok Voon Lee	135
@NP	,1 Joost Verhaagen ,3	158
@NP	Alan R.	179
@NP	Harvey1 ,2 and Giles W.	187
@NP	Harvey1	187
@NP	,2 and Giles W.	194
@NP	,2	194
@NP	Giles W.	201
@NP	Plant1	210
@NP	,2 Summary Adenoviral -LRB- AdV -RRB- vectors	216
@NP	,2	216
@NP	AdV	240
@NP	neurotrophin-3 -LRB- AdVNT -	262
@NP	neurotrophin-3	262
@NP	AdVNT	278
@NP	or	288
@NP	the bacterial marker	291
@NP	enzyme betta-galactosidase -LRB- LacZ gene -RRB-	312
@NP	enzyme betta-galactosidase	312
@NP	LacZ gene	340
@NP	olfactory ensheathing glia	374
@NP	-LRB- OEG -RRB- cultures	401
@NP	OEG	402
@NP	AdV vector-transduced OEG	417
@NP	high levels of recombinant neurotrophin	453
@NP	high levels	453
@NP	recombinant neurotrophin	468
@NP	in situ hybridization and enzyme-linked immunosorbent assay techniques	505
@NP	in situ hybridization	505
@NP	hybridization	513
@NP	enzyme-linked immunosorbent assay techniques	531
@NP	The biological activity of vector-derived NT-3	577
@NP	The biological activity	577
@NP	vector-derived NT-3	604
@NP	a dorsal root ganglia neurite outgrowth assay	642
@NP	Engineered cell suspensions	689
@NP	adult Fischer 344	741
@NP	rat spinal cord immediately after unilateral cervical -LRB- C4 -RRB-	759
@NP	rat spinal cord	759
@NP	unilateral cervical -LRB- C4 -RRB-	793
@NP	CST	839
@NP	animals	870
@NP	a total of 200 000 cells	887
@NP	a total	887
@NP	200 000 cells	898
@NP	nontransduced OEG or OEG	920
@NP	AdV vectors	961
@NP	NT-3 or LacZ	982
@NP	3 months after injury	1013
@NP	3 months	1013
@NP	injury	1028
@NP	lesion volumes	1036
@NP	all OEG-transplanted rats	1081
@NP	control	1126
@NP	-LRB- medium-injected -RRB- rats	1134
@NP	Anterograde tracing of the lesioned CST projection	1158
@NP	Anterograde	1158
@NP	the lesioned CST projection	1181
@NP	the contralateral sensorimotor cortex	1227
@NP	a significantly greater number of distal CST axons	1273
@NP	a significantly greater number	1273
@NP	distal CST axons	1307
@NP	OEG-NT-3	1332
@NP	transplanted rats	1342
@NP	Behavioural analysis	1361
@NP	all rats using open field locomotion scoring	1399
@NP	all rats	1399
@NP	open field locomotion scoring	1414
@NP	a forelimb reaching task with Eshkol -- Wachman movement notation	1449
@NP	a forelimb reaching task with Eshkol	1449
@NP	a forelimb	1449
@NP	task	1469
@NP	Eshkol	1479
@NP	Wachman movement notation	1486
@NP	Wachman	1486
@NP	movement notation	1494
@NP	Analysis of behavioural tests	1513
@NP	Analysis	1513
@NP	behavioural tests	1525
@NP	no significant differences	1552
@NP	recovery between experimental groups	1582
@NP	recovery	1582
@NP	experimental groups	1599
@NP	movement analysis	1629
@NP	possible compensatory mechanisms	1662
@NP	OEG implantation	1716
@NP	The results	1734
@NP	OEG transplantation	1763
@NP	tissue sparing	1802
@NP	injury	1823
@NP	appropriate genetic modification	1842
@NP	these olfactory-derived cells	1876
@NP	long-distance maintenance/regeneration of lesioned adult CST axons	1945
@NP	long-distance maintenance/regeneration	1945
@NP	lesioned adult CST axons	1987
@NP	Introduction The adult mammalian spinal cord	2014
@NP	Introduction	2014
@NP	The adult mammalian spinal cord	2027
@NP	axons	2092
@NP	injury	2104
@NP	part	2115
@NP	the growthinhibiting properties of the mature CNS	2127
@NP	the growthinhibiting properties	2127
@NP	the mature CNS	2162
@NP	Axonal regrowth within the spinal cord	2178
@NP	Axonal regrowth	2178
@NP	the spinal cord	2201
@NP	a certain extent	2250
@NP	the inhibitory microenvironment of the CNS , e.g.	2279
@NP	the inhibitory microenvironment	2279
@NP	the CNS	2314
@NP	neural cell transplantation	2332
@NP	olfactoryensheathing glia -LRB- OEG -RRB-	2368
@NP	olfactoryensheathing glia	2368
@NP	OEG	2395
@NP	the olfactory nerve layer of the olfactory bulb -LRB- e.g.	2442
@NP	the olfactory nerve layer	2442
@NP	the olfactory bulb -LRB- e.g.	2471
@NP	the olfactory bulb	2471
@NP	e.g.	2491
@NP	Ramon-Cueto et al. , 1998 ; Yan et al. , 2001 ; Plant et al. , 2003 -RRB- .	2496
@NP	Ramon-Cueto et al. , 1998	2496
@NP	Ramon-Cueto	2496
@NP	et al. , 1998	2508
@NP	et al.	2508
@NP	1998	2516
@NP	Yan et al. , 2001 ; Plant et al. , 2003 -RRB-	2522
@NP	Yan	2522
@NP	et al. , 2001 ; Plant et al. , 2003 -RRB-	2526
@NP	et al. , 2001 ; Plant et al.	2526
@NP	et al. , 2001	2526
@NP	et al.	2526
@NP	2001	2534
@NP	Plant et al.	2540
@NP	Plant	2540
@NP	et al.	2546
@NP	2003	2554
@NP	Previous studies	2561
@NP	a proportion of severed spinal cord axons	2601
@NP	a proportion	2601
@NP	spinal cord axons	2625
@NP	the presence	2670
@NP	OEG	2686
@NP	Ramon-Cueto and Nieto-Sampedro , 1994	2691
@NP	Ramon-Cueto and Nieto-Sampedro	2691
@NP	1994	2723
@NP	Li et al. , 1997 , 1998 , 2003	2729
@NP	Li	2729
@NP	et al. , 1997 , 1998 , 2003	2732
@NP	et al.	2732
@NP	1997	2740
@NP	1998	2746
@NP	2003	2752
@NP	Ramon-Cueto et al.	2758
@NP	Ramon-Cueto	2758
@NP	et al.	2770
@NP	1998 , 2000 ; Lu et al.	2778
@NP	1998 , 2000	2778
@NP	1998	2778
@NP	2000	2784
@NP	Lu et al.	2790
@NP	Lu	2790
@NP	et al.	2793
@NP	2001 , 2002	2801
@NP	2001	2801
@NP	2002	2807
@NP	Takami et al. , 2002	2813
@NP	Takami	2813
@NP	et al. , 2002	2820
@NP	et al.	2820
@NP	2002	2828
@NP	Keyvan-Fouladi et al. , 2003	2834
@NP	Keyvan-Fouladi	2834
@NP	et al. , 2003	2849
@NP	et al.	2849
@NP	2003	2857
@NP	Plant et al. , 2003	2863
@NP	Plant	2863
@NP	et al. , 2003	2869
@NP	et al.	2869
@NP	2003	2877
@NP	Chuah et al. , 2004	2883
@NP	Chuah	2883
@NP	et al. , 2004	2889
@NP	et al.	2889
@NP	2004	2897
@NP	Ramer et al. , 2004	2903
@NP	Ramer	2903
@NP	et al. , 2004	2909
@NP	et al.	2909
@NP	2004	2917
@NP	Primary OEG	2924
@NP	several trophic factors	2957
@NP	Ramon-Cueto and Avila , 1998 ; Boruch et al. , 2001 ; Woodhall et al. , 2001	2982
@NP	Ramon-Cueto and Avila	2982
@NP	Ramon-Cueto	2982
@NP	Avila	2998
@NP	1998 ; Boruch et al.	3005
@NP	1998	3005
@NP	Boruch et al.	3011
@NP	Boruch	3011
@NP	et al.	3018
@NP	2001 ; Woodhall et al. , 2001	3026
@NP	2001	3026
@NP	Woodhall et al. , 2001	3032
@NP	Woodhall	3032
@NP	et al. , 2001	3041
@NP	et al.	3041
@NP	2001	3049
@NP	their growth-permissive properties	3080
@NP	Trophic factors secreted by OEG	3116
@NP	Trophic factors	3116
@NP	OEG	3144
@NP	nerve growth factor	3156
@NP	neurotrophin-4 / 5 and neuregulin	3177
@NP	neurotrophin-4	3177
@NP	5 and neuregulin	3192
@NP	5	3192
@NP	neuregulin	3198
@NP	Thompson	3210
@NP	et al. , 2000 ; Boruch et al. , 2001	3219
@NP	et al.	3219
@NP	2000 ; Boruch et al.	3227
@NP	2000	3227
@NP	Boruch et al.	3233
@NP	Boruch	3233
@NP	et al.	3240
@NP	2001	3248
@NP	Brain-derived neurotrophic factor	3255
@NP	small amounts	3309
@NP	neurotrophin-3 -LRB- NT-3 -RRB-	3328
@NP	neurotrophin-3	3328
@NP	NT-3	3344
@NP	detectable quantities -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	3370
@NP	detectable quantities	3370
@NP	Boruch	3393
@NP	et al. , 2001 ; Woodhall et al. , 2001	3400
@NP	et al.	3400
@NP	2001 ; Woodhall et al.	3408
@NP	2001	3408
@NP	Woodhall et al.	3414
@NP	Woodhall	3414
@NP	et al.	3423
@NP	2001	3431
@NP	NT-3	3451
@NP	the regrowth of important motor pathways	3487
@NP	the regrowth	3487
@NP	important motor pathways	3503
@NP	spinal cord injuries	3534
@NP	particular the corticospinal tract -LRB- CST -RRB-	3559
@NP	particular the corticospinal tract	3559
@NP	CST	3595
@NP	combination with other factors	3611
@NP	combination	3611
@NP	other factors	3628
@NP	a single injection	3659
@NP	Schnell et al. , 1994 ; Grill et al. , 1997 ; Blits et al. , 2000	3679
@NP	Schnell	3679
@NP	et al. , 1994 ; Grill et al. , 1997 ; Blits et al. , 2000	3687
@NP	et al. , 1994	3687
@NP	et al.	3687
@NP	1994	3695
@NP	Grill et al. , 1997	3701
@NP	Grill	3701
@NP	et al. , 1997	3707
@NP	et al.	3707
@NP	1997	3715
@NP	Blits et al. , 2000	3721
@NP	Blits	3721
@NP	et al. , 2000	3727
@NP	et al.	3727
@NP	2000	3735
@NP	Adult CST neurons	3742
@NP	the high affinity receptor for NT	3768
@NP	the high affinity receptor	3768
@NP	NT	3799
@NP	3	3803
@NP	TrkC -LRB- Giehl and Tetzlaff , 1996 -RRB-	3806
@NP	TrkC	3806
@NP	Giehl and Tetzlaff , 1996	3812
@NP	Giehl	3812
@NP	Tetzlaff , 1996	3822
@NP	Tetzlaff	3822
@NP	1996	3832
@NP	injury -LRB- Liebl et al. , 2001 -RRB-	3877
@NP	injury	3877
@NP	Liebl	3885
@NP	et al. , 2001	3891
@NP	et al.	3891
@NP	2001	3899
@NP	this neurotrophin	3912
@NP	a critical factor in CST growth and plasticity	3944
@NP	a critical factor	3944
@NP	CST growth and plasticity	3965
@NP	CST growth	3965
@NP	plasticity	3980
@NP	It	3992
@NP	us -LRB- Ruitenberg et al. , 2003 -RRB- and others -LRB- Cao et al. , 2004 -RRB-	4017
@NP	us	4017
@NP	Ruitenberg	4021
@NP	et al. , 2003	4032
@NP	et al.	4032
@NP	2003	4040
@NP	others	4050
@NP	Cao	4058
@NP	et al. , 2004	4062
@NP	et al.	4062
@NP	2004	4070
@NP	genetic engineering of OEG	4081
@NP	genetic engineering	4081
@NP	OEG	4104
@NP	a cell type that is more effective in promoting spinal cord repair	4122
@NP	a cell type	4122
@NP	spinal cord repair	4170
@NP	Our previous study	4190
@NP	injury and regeneration	4220
@NP	the rubrospinal tract -LRB- Ruitenberg et al. , 2003 -RRB-	4247
@NP	the rubrospinal tract	4247
@NP	Ruitenberg	4270
@NP	et al. , 2003	4281
@NP	et al.	4281
@NP	2003	4289
@NP	the present study	4299
@NP	the specific aim	4323
@NP	an environment	4353
@NP	CST regrowth	4386
@NP	injury	4405
@NP	we	4413
@NP	adult OEG	4427
@NP	NT-3	4448
@NP	an ex vivo adenoviral -LRB- AdV -RRB- vector transduction technique	4459
@NP	ex vivo adenoviral -LRB- AdV -RRB-	4462
@NP	ex vivo adenoviral	4462
@NP	ex vivo	4462
@NP	AdV	4482
@NP	Ruitenberg	4518
@NP	et al. , 2002a	4529
@NP	et al.	4529
@NP	2002a	4537
@NP	These modified OEG	4545
@NP	the injured rat cervical spinal cord	4590
@NP	the injured rat	4590
@NP	cervical spinal cord	4606
@NP	a unilateral CST lesion	4633
@NP	We	4658
@NP	the novel approach	4666
@NP	left and right CST projections	4705
@NP	different biotin dextran labels	4742
@NP	us	4789
@NP	the interplay of lesioned	4818
@NP	the interplay	4818
@NP	intact descending axonal tracts in control and OEGtransplanted rats	4851
@NP	intact descending axonal tracts	4851
@NP	control and OEGtransplanted rats	4886
@NP	Behavioural analysis	4920
@NP	a 3 month time period	4959
@NP	open field locomotion -LRB- Basso et al. , 1995 -RRB-	4987
@NP	open field locomotion	4987
@NP	Basso	5010
@NP	et al. , 1995	5016
@NP	et al.	5016
@NP	1995	5024
@NP	pellet retrieval -LRB- Thallmair et al. , 1998 -RRB-	5031
@NP	pellet retrieval	5031
@NP	Thallmair	5049
@NP	et al. , 1998	5059
@NP	et al.	5059
@NP	1998	5067
@NP	movement analysis	5077
@NP	Whishaw	5096
@NP	et al. , 1993	5104
@NP	et al.	5104
@NP	1993	5112
@NP	Material and methods Animals Adult female Fischer 344 rats	5120
@NP	Material and methods Animals	5120
@NP	Adult female Fischer 344 rats	5149
@NP	120	5180
@NP	150 g ; Animal Resource Center , Australia	5184
@NP	150 g	5184
@NP	Animal Resource Center , Australia	5191
@NP	the in vivo study of spinal cord injury	5240
@NP	study of spinal cord injury	5252
@NP	study	5252
@NP	spinal cord injury	5261
@NP	analysis of the behaviour resulting from such an injury	5284
@NP	analysis	5284
@NP	the behaviour resulting from such an injury	5296
@NP	the behaviour	5296
@NP	such an injury	5325
@NP	All experimental procedures	5341
@NP	National Health and Medical Research Council guidelines -LRB- Australia -RRB-	5382
@NP	National Health and Medical Research Council guidelines	5382
@NP	Australia	5439
@NP	The University of Western Australia Animal Ethics Committee	5471
@NP	The University	5471
@NP	Western Australia Animal Ethics Committee	5489
@NP	Rats	5532
@NP	90 % of normal body weight	5556
@NP	90 %	5556
@NP	normal body weight	5563
@NP	amounts of food each day	5608
@NP	amounts	5608
@NP	food each day	5619
@NP	food	5619
@NP	each day	5624
@NP	This	5634
@NP	a constant appetite	5653
@NP	the animals	5681
@NP	the food pellet retrieval task -LRB- Whishaw and Pellis , 1990 -RRB-	5719
@NP	the food pellet retrieval task	5719
@NP	Whishaw and Pellis , 1990	5751
@NP	Whishaw	5751
@NP	Pellis , 1990	5763
@NP	Pellis	5763
@NP	1990	5771
@NP	29 rats	5789
@NP	behaviour analysis for 2 weeks prior to surgery	5814
@NP	behaviour analysis	5814
@NP	2 weeks prior to surgery	5837
@NP	2 weeks	5837
@NP	surgery	5854
@NP	two	5863
@NP	the task	5888
@NP	the experiment	5920
@NP	The remaining 27 animals	5936
@NP	surgery	5971
@NP	the end of the pre-training period	5982
@NP	the end	5982
@NP	the pre-training period	5993
@NP	2 weeks	6034
@NP	recovery	6042
@NP	post-injury behavioural testing	6058
@NP	Analysis of forelimb function using the forelimb reaching task	6091
@NP	Analysis	6091
@NP	forelimb function using the forelimb reaching task	6103
@NP	forelimb function	6103
@NP	the forelimb	6127
@NP	task	6149
@NP	three times	6173
@NP	a week	6185
@NP	10 weeks , before the animals were sacrificed for histological analysis	6208
@NP	10 weeks	6208
@NP	the animals	6225
@NP	histological analysis	6257
@NP	OEG cultures from adult rat OEG	6280
@NP	OEG cultures	6280
@NP	adult rat OEG	6298
@NP	the olfactory bulb nerve layer	6332
@NP	adult female Fischer 344 rats -LRB- 8 weeks old , 200 g ; n = 5 -RRB-	6366
@NP	adult female Fischer 344 rats	6366
@NP	8 weeks old , 200 g ; n = 5	6397
@NP	8 weeks old	6397
@NP	200 g ; n = 5	6410
@NP	200 g	6410
@NP	n = 5	6417
@NP	n	6417
@NP	5	6421
@NP	Plant	6440
@NP	et al. -LRB- 2003 -RRB-	6446
@NP	et al.	6446
@NP	2003	6454
@NP	brief	6464
@NP	the olfactory nerve layer	6471
@NP	the ventral part of the olfactory bulbs	6521
@NP	the ventral part	6521
@NP	the olfactory bulbs	6541
@NP	small pieces	6573
@NP	0.25 % trypsin -LRB- Gibco-BRL , USA -RRB-	6605
@NP	0.25 % trypsin	6605
@NP	Gibco-BRL	6620
@NP	USA	6631
@NP	50 mg/ml DNase -LRB- Boehringer Mannheim , Germany -RRB-	6640
@NP	50 mg/ml DNase	6640
@NP	Boehringer Mannheim	6656
@NP	Germany	6677
@NP	Hank 's	6689
@NP	salt solution -LRB- HBSS ; Sigma , USA -RRB- for 60 min	6705
@NP	salt solution -LRB- HBSS ; Sigma , USA -RRB-	6705
@NP	salt solution	6705
@NP	HBSS ; Sigma , USA	6720
@NP	HBSS	6720
@NP	Sigma , USA	6726
@NP	60 min	6742
@NP	37 °C	6752
@NP	The tissue	6758
@NP	a single cell suspension	6795
@NP	Cells	6834
@NP	low-speed centrifugation	6858
@NP	poly-L-lysine	6913
@NP	-LRB- PLL ; Sigma -RRB- coated dishes	6928
@NP	PLL ; Sigma	6929
@NP	PLL	6929
@NP	Sigma	6934
@NP	The medium	6956
@NP	3	6986
@NP	4 days and OEG	6988
@NP	4 days	6988
@NP	OEG	6999
@NP	another 4 days	7017
@NP	contaminating cells	7065
@NP	the low affinity nerve growth factor receptor p75 antibody	7091
@NP	Plant	7151
@NP	et al. , 2002	7157
@NP	et al.	7157
@NP	2002	7165
@NP	AdV vector infection	7172
@NP	transgene expression analysis	7197
@NP	optimal transduction	7246
@NP	primary OEG cultures	7270
@NP	Ruitenberg et al. , 2002a	7322
@NP	Ruitenberg	7322
@NP	et al.	7333
@NP	2002a	7341
@NP	OEG	7349
@NP	AdV vectors	7372
@NP	LacZ or NT-3	7401
@NP	a multiplicity of infection -LRB- m.o.i. -RRB- of 100	7418
@NP	a multiplicity	7418
@NP	infection -LRB- m.o.i. -RRB- of 100	7436
@NP	infection -LRB- m.o.i. -RRB-	7436
@NP	infection	7436
@NP	m.o.i.	7447
@NP	100	7458
@NP	The calculated dose of recombinant virus	7463
@NP	The calculated dose	7463
@NP	recombinant virus	7486
@NP	the culture medium	7517
@NP	the cells overnight in a 37 °C tissue culture incubator	7555
@NP	the cells overnight	7555
@NP	a 37 °C tissue culture incubator	7578
@NP	Next day	7611
@NP	virus-containing medium	7621
@NP	fresh medium	7663
@NP	the cells	7680
@NP	48 h	7699
@NP	initiation of transgene expression	7713
@NP	initiation	7713
@NP	transgene expression	7727
@NP	AdV vector-transduced cells	7749
@NP	expression of the LacZ gene	7801
@NP	expression	7801
@NP	the LacZ gene	7815
@NP	X-gal histochemistry	7835
@NP	NT-3 mRNA expression using standard non-radioactive in situ	7872
@NP	NT-3 mRNA expression	7872
@NP	standard non-radioactive in situ	7899
@NP	standard non-radioactive	7899
@NP	situ	7927
@NP	hybridization techniques	7932
@NP	Secretion and biological activity of AdV vector-derived NT-3	7958
@NP	Secretion and biological activity	7958
@NP	AdV vector-derived NT-3	7995
@NP	transplantation	8051
@NP	Conditioned media from non-modified OEG -	8068
@NP	Conditioned media	8068
@NP	non-modified OEG	8091
@NP	AdV-LacZ - or AdV-NT-3 - -LRB- OEG-LacZ and OEG-NT-3 , respectively -RRB-	8110
@NP	AdV-LacZ - or AdV-NT-3 -	8110
@NP	AdV-LacZ	8110
@NP	AdV-NT-3	8123
@NP	OEG-LacZ and OEG-NT-3 , respectively	8134
@NP	OEG-LacZ and OEG-NT-3	8134
@NP	cell cultures	8182
@NP	the presence	8214
@NP	AdV vector-derived NT-3	8230
@NP	an enzymelinked immunosorbent assay -LRB- ELISA ; Ruitenberg et al. , 2003 -RRB-	8260
@NP	an enzymelinked immunosorbent assay	8260
@NP	ELISA ; Ruitenberg et al. , 2003	8297
@NP	ELISA	8297
@NP	Ruitenberg et al. , 2003	8304
@NP	Ruitenberg	8304
@NP	et al. , 2003	8315
@NP	et al.	8315
@NP	2003	8323
@NP	The EmaxTM immunoassay system -LRB- Promega , USA -RRB-	8330
@NP	The EmaxTM immunoassay system	8330
@NP	Promega	8361
@NP	USA	8370
@NP	levels of NT-3 in OEG-conditioned medium	8397
@NP	levels	8397
@NP	NT-3 in OEG-conditioned medium	8407
@NP	NT-3	8407
@NP	OEG-conditioned medium	8415
@NP	the manufacturer 's instructions	8451
@NP	the manufacturer 's	8451
@NP	The amount of secreted NT-3	8484
@NP	The amount	8484
@NP	NT-3	8507
@NP	ng of NT-3 derived from a transduced culture per day	8529
@NP	ng	8529
@NP	NT-3 derived from a transduced culture per day	8535
@NP	NT-3	8535
@NP	a transduced culture per day	8553
@NP	a	8553
@NP	culture per day	8566
@NP	culture	8566
@NP	day	8578
@NP	The biological activity of AdV vector-derived NT-3	8583
@NP	The biological activity	8583
@NP	AdV vector-derived NT-3	8610
@NP	assaying neurite outgrowth from dorsal root ganglion -LRB- DRG -RRB- explants	8652
@NP	assaying neurite outgrowth	8652
@NP	dorsal root ganglion -LRB- DRG -RRB- explants	8684
@NP	the methods of Dijkhuizen	8732
@NP	the methods	8732
@NP	Dijkhuizen	8747
@NP	et al. -LRB- 1997 -RRB-	8758
@NP	et al.	8758
@NP	1997	8766
@NP	Embryonic day	8773
@NP	15 -LRB- E15 -RRB-	8787
@NP	15	8787
@NP	E15	8791
@NP	DRG explants	8796
@NP	48 h in the presence of conditioned medium	8824
@NP	48 h	8824
@NP	the presence of conditioned medium	8832
@NP	the presence	8832
@NP	conditioned medium	8848
@NP	OEG cultures	8872
@NP	AdV-NT - 3 , AdV-LacZ or no virus	8899
@NP	AdV-NT	8899
@NP	3 , AdV-LacZ or no virus	8907
@NP	3	8907
@NP	AdV-LacZ	8910
@NP	no virus	8922
@NP	Neurite outgrowth	8946
@NP	the mouse monoclonal antibody 2H3	8984
@NP	neurofilament	9026
@NP	1 : 1000 ; Developmental Hybridoma Bank , University of Iowa	9041
@NP	1 : 1000	9041
@NP	Developmental Hybridoma Bank , University of Iowa	9051
@NP	Developmental Hybridoma Bank , University	9051
@NP	Iowa	9095
@NP	IA , USA	9101
@NP	IA	9101
@NP	USA	9105
@NP	Photo images	9111
@NP	an IX70 inverted microscope -LRB- Olympus , Melbourne , Australia -RRB-	9141
@NP	an IX70 inverted microscope	9141
@NP	Olympus	9170
@NP	Melbourne	9179
@NP	Australia	9190
@NP	a Magnafire Digital camera -LRB- Optronics , USA -RRB-	9206
@NP	a Magnafire Digital camera	9206
@NP	Optronics	9234
@NP	USA	9245
@NP	In vivo analysis of transgene expression	9251
@NP	In vivo analysis	9251
@NP	transgene expression	9271
@NP	three rats	9309
@NP	7 days	9323
@NP	post-OEG implantation	9330
@NP	sagittal sections	9358
@NP	the cervical spinal cord	9384
@NP	standard in situ hybridization using digoxygenin -LRB- DIG -RRB-	9432
@NP	standard	9432
@NP	hybridization	9449
@NP	digoxygenin -LRB- DIG -RRB-	9469
@NP	digoxygenin	9469
@NP	DIG	9482
@NP	cRNA antisense probe against NT-3 mRNA -LRB- Ruitenberg et al. , 2003 -RRB-	9496
@NP	cRNA antisense probe	9496
@NP	NT-3 mRNA -LRB- Ruitenberg et al. , 2003 -RRB-	9525
@NP	NT-3 mRNA	9525
@NP	Ruitenberg	9536
@NP	et al. , 2003	9547
@NP	et al.	9547
@NP	2003	9555
@NP	In vitro characterization	9562
@NP	OEG	9602
@NP	The purity of OEG cultures used for transplantation	9606
@NP	The purity	9606
@NP	OEG cultures used for transplantation	9620
@NP	OEG cultures	9620
@NP	transplantation	9642
@NP	immunocytochemistry for antigenic OEG markers	9675
@NP	immunocytochemistry	9675
@NP	antigenic OEG markers	9699
@NP	Glial fibrillary acidic protein -LRB- GFAP -RRB- and S100 protein	9722
@NP	Glial fibrillary acidic protein -LRB- GFAP -RRB-	9722
@NP	Glial fibrillary acidic protein	9722
@NP	GFAP	9755
@NP	S100 protein	9765
@NP	rabbit anti-cow GFAP	9797
@NP	DAKO Corp.	9819
@NP	USA	9831
@NP	rabbit anti-S100	9839
@NP	then	9875
@NP	Alexa Fluor1-488	9896
@NP	goat anti-rabbit IgG -LRB- Vector Laboratories Inc. , USA -RRB-	9924
@NP	goat anti-rabbit IgG	9924
@NP	Vector Laboratories Inc. , USA	9946
@NP	Vector Laboratories Inc.	9946
@NP	USA	9972
@NP	Immunoreactivity for low-affinity nerve growth factor receptor p75	9978
@NP	Immunoreactivity	9978
@NP	low-affinity nerve growth factor receptor p75	9999
@NP	Jackson ImmunoResearch Laboratories Inc. , USA	10151
@NP	Jackson ImmunoResearch Laboratories Inc.	10151
@NP	USA	10193
@NP	OEG purity	10199
@NP	the ratio of p75-positive cells	10230
@NP	the ratio	10230
@NP	p75-positive cells	10243
@NP	the total cell number -LRB- nuclear stain ; Hoechst 33342 dye -RRB-	10265
@NP	the total cell number	10265
@NP	nuclear stain ; Hoechst 33342 dye	10288
@NP	Hoechst 33342 dye	10303
@NP	Hoechst 33342	10303
@NP	the culture	10325
@NP	transgenic NT-3	10352
@NP	a mitogenic effect on adult OEG derived from the olfactory bulb nerve layer	10372
@NP	a mitogenic effect	10372
@NP	adult OEG derived from the olfactory bulb nerve layer	10394
@NP	adult OEG	10394
@NP	the olfactory bulb nerve layer	10417
@NP	cell proliferation	10449
@NP	bromodeoxyuridine -LRB- BrdU ; Roche , Germany -RRB- incorporation	10492
@NP	bromodeoxyuridine -LRB- BrdU ; Roche , Germany -RRB-	10492
@NP	bromodeoxyuridine	10492
@NP	BrdU ; Roche , Germany	10511
@NP	BrdU	10511
@NP	Roche , Germany	10517
@NP	incorporation	10533
@NP	OEG	10557
@NP	PLL-coated coverslips -LRB- 15 000 cells/12 mm coverslip -RRB- in a 1	10610
@NP	PLL-coated coverslips -LRB- 15 000 cells/12 mm coverslip -RRB-	10610
@NP	PLL-coated coverslips	10610
@NP	15 000 cells/12 mm coverslip	10633
@NP	15 000	10633
@NP	cells/12 mm coverslip	10640
@NP	a 1	10666
@NP	1 mixture of Dulbecco 's modified Eagle 's medium -LRB- DMEM ; Sigma -RRB-	10672
@NP	1 mixture	10672
@NP	Dulbecco 's	10685
@NP	Eagle 's medium -LRB- DMEM ; Sigma -RRB-	10705
@NP	Eagle 's medium	10705
@NP	Eagle 's	10705
@NP	DMEM ; Sigma	10721
@NP	DMEM	10721
@NP	Sigma	10727
@NP	Ham 's F-12 nutrient mix -LRB- DF medium -RRB-	10738
@NP	Ham 's F-12 nutrient mix	10738
@NP	Ham 's	10738
@NP	DF medium	10763
@NP	10 % fetal bovine serum -LRB- DF-10S -RRB- plus mitogens	10793
@NP	10 % fetal bovine serum	10793
@NP	DF-10S	10817
@NP	mitogens	10830
@NP	pituitary extract -LRB- 2 µg/ml ; Sigma -RRB-	10839
@NP	pituitary extract	10839
@NP	2 µg/ml ; Sigma	10858
@NP	2 µg/ml	10858
@NP	Sigma	10867
@NP	forskolin -LRB- 0.2 µM ; Sigma -RRB-	10878
@NP	forskolin	10878
@NP	0.2 µM ; Sigma	10889
@NP	0.2 µM	10889
@NP	Sigma	10897
@NP	The following day	10905
@NP	the medium	10924
@NP	either serum-free chemically defined -LRB- CD -RRB-	10953
@NP	serum-free	10960
@NP	CD	10991
@NP	Yan et al. , 2001	11003
@NP	Yan	11003
@NP	et al.	11007
@NP	2001	11015
@NP	mitogen-containing DF-10S	11031
@NP	the cells	11062
@NP	48 h.	11086
@NP	Twelve OEG cultures growing in CD medium	11092
@NP	Twelve OEG cultures	11092
@NP	CD medium	11123
@NP	AdV-LacZ or AdV-NT-3 -LRB- 2 x n = 6 ; m.o.i. 100 -RRB- as described above	11159
@NP	AdV-LacZ or AdV-NT-3	11159
@NP	2 x n = 6 ; m.o.i. 100	11181
@NP	2 x	11181
@NP	n = 6 ; m.o.i. 100	11185
@NP	n = 6	11185
@NP	n	11185
@NP	6	11189
@NP	m.o.i. 100	11192
@NP	Additional cultures	11224
@NP	triplicate per experimental condition	11258
@NP	triplicate	11258
@NP	experimental condition	11273
@NP	CD medium	11307
@NP	DF-10S plus mitogens	11323
@NP	DF-10S	11323
@NP	mitogens	11335
@NP	the addition	11349
@NP	increasing amounts	11365
@NP	recombinant NT-3	11387
@NP	0 , 1 , 10 , 25 , 50 and 100 ng/ml ; Peprotech Inc. , USA	11405
@NP	0	11405
@NP	1	11408
@NP	10	11411
@NP	25	11415
@NP	50	11419
@NP	100 ng/ml ; Peprotech Inc. , USA	11426
@NP	100 ng/ml	11426
@NP	Peprotech Inc. , USA	11437
@NP	Peprotech Inc.	11437
@NP	USA	11453
@NP	The latter experimental groups	11459
@NP	new medium containing freshly thawed NT-3	11510
@NP	new medium	11510
@NP	NT-3	11547
@NP	One day	11553
@NP	the first exposure to NT-3	11567
@NP	the first exposure	11567
@NP	NT-3	11589
@NP	all cultures	11595
@NP	10 µM BrdU	11625
@NP	24 h prior to fixation	11654
@NP	24 h	11654
@NP	fixation	11668
@NP	Uptake of BrdU by dividing cells under the different experimental conditions	11678
@NP	Uptake	11678
@NP	BrdU by dividing cells under the different experimental conditions	11688
@NP	BrdU	11688
@NP	cells	11705
@NP	the different experimental conditions	11717
@NP	immunocytochemistry	11772
@NP	a polyclonal sheep anti-BrdU antibody	11798
@NP	1 : 1600 ; Fitzgerald , USA	11837
@NP	1 : 1600	11837
@NP	Fitzgerald , USA	11847
@NP	monoclonal S100 antibody	11868
@NP	1 : 1000 ; Sigma	11894
@NP	1 : 1000	11894
@NP	Sigma	11904
@NP	OEG	11923
@NP	Per experimental condition -LRB- n = 3 -RRB-	11928
@NP	Per experimental condition	11928
@NP	n	11956
@NP	3	11960
@NP	photo images	11964
@NP	five random fields across each coverslip for cell counts	11991
@NP	five random fields	11991
@NP	each coverslip for cell counts	12017
@NP	each coverslip	12017
@NP	cell counts	12036
@NP	The fraction of proliferating cells	12049
@NP	The fraction	12049
@NP	proliferating cells	12065
@NP	the ratio of BrdU-positive cells	12105
@NP	the ratio	12105
@NP	BrdU-positive cells	12118
@NP	the total cell number -LRB- Hoechst -RRB-	12141
@NP	the total cell number	12141
@NP	Hoechst	12164
@NP	The whole experiment	12174
@NP	A total of just over 72 000 cells	12215
@NP	A total	12215
@NP	just over 72 000 cells	12226
@NP	this experiment	12265
@NP	an average number of 824 ± 34	12287
@NP	an average number	12287
@NP	824 ± 34	12308
@NP	3006 ± 75 cells	12321
@NP	experimental condition in serum-free and mitogencontaining medium	12349
@NP	experimental condition	12349
@NP	serum-free and mitogencontaining medium	12375
@NP	The biological activity of recombinant NT-3 -LRB- 50 ng/ml -RRB-	12430
@NP	The biological activity of recombinant NT-3	12430
@NP	The biological activity	12430
@NP	recombinant NT-3	12457
@NP	50 ng/ml	12475
@NP	culture using E15 DRG explants -LRB- prepared as described above -RRB-	12502
@NP	culture	12502
@NP	E15 DRG explants	12516
@NP	Explants -LRB- n = 6 -RRB-	12564
@NP	Explants	12564
@NP	n	12574
@NP	6	12578
@NP	NeurobasalTM medium -LRB- Gibco -RRB- for 72 h.	12595
@NP	NeurobasalTM medium -LRB- Gibco -RRB-	12595
@NP	NeurobasalTM medium	12595
@NP	Gibco	12616
@NP	72 h.	12627
@NP	Explant cultures	12633
@NP	nuclear Hoechst	12680
@NP	antibodies	12704
@NP	pan-neurofilament -LRB- 1 : 500 ; Zymed , USA -RRB- and S100 protein	12723
@NP	pan-neurofilament -LRB- 1 : 500 ; Zymed , USA -RRB-	12723
@NP	pan-neurofilament	12723
@NP	1 : 500 ; Zymed , USA	12742
@NP	1 : 500	12742
@NP	Zymed , USA	12751
@NP	S100 protein	12767
@NP	standard immunohistochemical techniques	12786
@NP	Spinal cord surgery The methods	12827
@NP	Spinal cord surgery	12827
@NP	The methods	12847
@NP	spinal cord surgery and cell suspension injections	12863
@NP	Ruitenberg	12941
@NP	et al. , 2002a , b	12952
@NP	et al.	12952
@NP	2002a	12960
@NP	b	12966
@NP	the 27 operated rats	12973
@NP	the 27	12973
@NP	rats	12989
@NP	seven	12995
@NP	injections of OEG-NT-3	13010
@NP	injections	13010
@NP	OEG-NT-3	13024
@NP	a 1	13036
@NP	1 vehicle mix of DF medium , seven	13042
@NP	1 vehicle mix	13042
@NP	DF medium , seven	13059
@NP	DF medium	13059
@NP	seven	13070
@NP	OEG-LacZ	13095
@NP	seven	13105
@NP	non-modified OEG	13120
@NP	another six	13141
@NP	vehicle	13172
@NP	Two rats	13187
@NP	the surgery	13217
@NP	another animal	13233
@NP	weight , reacting adversely to the injury ,	13266
@NP	weight	13266
@NP	the injury	13296
@NP	the first postoperative week	13347
@NP	24 animals	13382
@NP	post-lesion analysis of behaviour	13407
@NP	post-lesion analysis	13407
@NP	behaviour	13431
@NP	An additional three rats	13442
@NP	NT-3 mRNA expression in OEG transplants in vivo	13489
@NP	NT-3 mRNA expression	13489
@NP	OEG transplants in vivo	13513
@NP	OEG transplants	13513
@NP	vivo	13532
@NP	surgery	13554
@NP	animals	13563
@NP	halothane	13595
@NP	1.5 % halothane	13606
@NP	1.5 %	13606
@NP	halothane	13611
@NP	Rhone-Poulenc Chemicals Pty Ltd , Australia	13622
@NP	Rhone-Poulenc Chemicals Pty Ltd	13622
@NP	Australia	13655
@NP	-LRB- v/v -RRB- in 60 % N2O/38 .5 % O2 -RSB-	13666
@NP	-LRB- v/v -RRB-	13666
@NP	60 % N2O/38 .5 % O2 -RSB-	13675
@NP	60 % N2O/38	13675
@NP	.5 % O2 -RSB-	13685
@NP	A rostral to caudal incision	13694
@NP	A rostral	13694
@NP	caudal incision	13707
@NP	the skin covering the cervical neck region , and the underlying shoulder	13735
@NP	the skin	13735
@NP	the cervical neck region	13753
@NP	the underlying shoulder	13783
@NP	muscles	13816
@NP	forceps	13845
@NP	Laminectomy of the C4 vertebra	13854
@NP	Laminectomy	13854
@NP	the C4 vertebra	13869
@NP	the dura	13903
@NP	the spinal cord	13940
@NP	A specially designed micro-knife	13957
@NP	a 1.5 mm deep medio-lateral incision	14012
@NP	1.5 mm	14014
@NP	the right half	14056
@NP	the spinal cord	14074
@NP	the dorsal hemisphere	14115
@NP	the CST	14158
@NP	A Hamilton syringe -LRB- 5 µl ; Bonaduz , Switzerland -RRB-	14167
@NP	A Hamilton syringe	14167
@NP	5 µl ; Bonaduz , Switzerland	14187
@NP	5 µl	14187
@NP	Bonaduz , Switzerland	14193
@NP	an attached capillary needle -LRB- tip diameter : 60 µm -RRB-	14220
@NP	an attached capillary needle	14220
@NP	tip diameter : 60 µm	14250
@NP	tip diameter	14250
@NP	60 µm	14264
@NP	each animal	14288
@NP	two injections -LRB- 2x 1 µl ; each containing 100 000 cells -RRB- of OEGNT	14300
@NP	two injections -LRB- 2x 1 µl ; each containing 100 000 cells -RRB-	14300
@NP	two injections	14300
@NP	2x 1 µl ; each containing 100 000 cells	14316
@NP	2x 1 µl	14316
@NP	each containing 100 000 cells	14325
@NP	each	14325
@NP	100 000 cells	14341
@NP	OEGNT	14359
@NP	3 , OEG-LacZ , non-transduced OEG or medium alone	14366
@NP	3	14366
@NP	OEG-LacZ	14369
@NP	non-transduced OEG	14379
@NP	medium alone	14401
@NP	OEG suspensions for implantation purposes	14415
@NP	OEG suspensions	14415
@NP	implantation purposes	14435
@NP	Ruitenberg	14498
@NP	et al. -LRB- 2002a -RRB-	14509
@NP	et al.	14509
@NP	2002a	14517
@NP	The researcher performing spinal surgery and OEG implantation	14525
@NP	The researcher	14525
@NP	spinal surgery and OEG implantation	14551
@NP	spinal surgery	14551
@NP	OEG implantation	14570
@NP	transplant conditions	14602
@NP	Injections	14625
@NP	0.5 mm lateral	14646
@NP	the dorso-medial sulcus on the right side of the spinal cord	14664
@NP	the dorso-medial sulcus	14664
@NP	the right side of the spinal cord	14691
@NP	the right side	14691
@NP	the spinal cord	14709
@NP	a depth of 0.8 mm in an attempt	14728
@NP	a depth	14728
@NP	0.8 mm in an attempt	14739
@NP	0.8 mm	14739
@NP	an attempt	14749
@NP	theOEGwithin	14769
@NP	the dorsalCSTprojection area	14782
@NP	The first injection	14812
@NP	1 mm proximal to the lesion and the second 1 mm	14841
@NP	1 mm	14841
@NP	the lesion and the second 1 mm	14857
@NP	the lesion	14857
@NP	the second 1 mm	14872
@NP	the lesion	14898
@NP	Shoulder muscles	14910
@NP	the skin	14958
@NP	Michel surgical clips -LRB- Fine Science Tools , Canada -RRB-	14983
@NP	Michel surgical clips	14983
@NP	Fine Science Tools , Canada	15006
@NP	Fine Science Tools	15006
@NP	Canada	15026
@NP	the first week	15042
@NP	animals	15058
@NP	subcutaneous injections	15077
@NP	benacillin	15104
@NP	150 mg/ml procaine penicillin , 150 mg/ml benzathine penicillin	15116
@NP	150 mg/ml procaine penicillin	15116
@NP	150 mg/ml benzathine penicillin	15147
@NP	20 mg/ml procaine hydrochloride ; Troy Laboratories Pty Ltd , Australia	15180
@NP	20 mg/ml procaine hydrochloride	15180
@NP	Troy Laboratories Pty Ltd , Australia	15213
@NP	Troy Laboratories Pty Ltd	15213
@NP	Australia	15240
@NP	every second day	15251
@NP	daily injections -LRB- 0.3 ml -RRB-	15272
@NP	daily injections	15272
@NP	0.3 ml	15290
@NP	the analgesic buprenorphine hydrochloride	15301
@NP	0.3 ml	15344
@NP	Reckitt and Colman	15352
@NP	UK	15372
@NP	Behavioural analysis BBB	15377
@NP	field	15407
@NP	scoring Functional performance of impaired fore - to hindlimb coordination	15413
@NP	scoring Functional performance	15413
@NP	impaired fore	15447
@NP	hindlimb coordination	15465
@NP	two independent investigators , blinded to the experimental treatment ,	15507
@NP	two independent investigators	15507
@NP	the experimental treatment	15549
@NP	the Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale	15583
@NP	Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	15587
@NP	Basso -- Beattie -- Bresnahan	15587
@NP	Beattie	15593
@NP	BBB	15612
@NP	Basso	15641
@NP	et al. , 1995	15647
@NP	et al.	15647
@NP	1995	15655
@NP	task and movement analysis	15680
@NP	The test apparatus	15707
@NP	a clear Perspex test box	15730
@NP	an opening	15760
@NP	the right side	15774
@NP	the anterior wall	15792
@NP	an external shelf on which to place food pellets -LRB- see Fig. 2 -RRB-	15814
@NP	an external shelf on which to place food pellets	15814
@NP	an external shelf	15814
@NP	food pellets	15850
@NP	Fig. 2	15868
@NP	The floor of the box	15877
@NP	The floor	15877
@NP	the box	15890
@NP	a metal grating	15911
@NP	a metal	15911
@NP	any	15933
@NP	food pellets	15945
@NP	Dustless precision pellets -LRB- 45 mg ; BioServ , USA -RRB-	15982
@NP	Dustless precision pellets	15982
@NP	45 mg ; BioServ , USA	16010
@NP	45 mg	16010
@NP	BioServ , USA	16017
@NP	this task	16045
@NP	they	16059
@NP	the rats to grasp easily	16086
@NP	an attractive reward	16124
@NP	Food pellets	16146
@NP	2.5 cm	16171
@NP	the inner edge	16183
@NP	the left side	16210
@NP	the shelf to encourage the animals to reach with the right forelimb	16227
@NP	the animals	16250
@NP	the right forelimb	16276
@NP	Each pellet	16296
@NP	another irrespective of whether it was eaten or dropped	16338
@NP	another irrespective	16338
@NP	it	16370
@NP	A successful reach	16395
@NP	the rat	16428
@NP	the opening	16452
@NP	the food pellet	16473
@NP	its right paw	16494
@NP	it	16524
@NP	its mouth	16530
@NP	Successful reaches with the left forelimb	16541
@NP	Successful reaches	16541
@NP	the left forelimb	16565
@NP	An unsuccessful reach	16600
@NP	the food pellet	16634
@NP	the test box	16669
@NP	the food pellet	16686
@NP	the shelf outside the test box	16731
@NP	the shelf	16731
@NP	the test box	16749
@NP	this	16763
@NP	the pellet	16787
@NP	Averaged weekly success ratings	16812
@NP	i.e. the number of successful reaches performed in 2 min	16845
@NP	i.e. the number	16845
@NP	i.e.	16845
@NP	the number	16850
@NP	successful reaches performed in 2 min	16864
@NP	successful reaches	16864
@NP	2 min	16896
@NP	three independent measurements over a 7 day period	16924
@NP	three independent measurements	16924
@NP	a 7 day period	16960
@NP	the analysis of movements involved in the forelimb reaching task	16980
@NP	the analysis	16980
@NP	movements involved in the forelimb reaching task	16996
@NP	movements	16996
@NP	the forelimb reaching task	17018
@NP	the forelimb	17018
@NP	task	17040
@NP	animals	17046
@NP	once a week	17066
@NP	three different angles	17083
@NP	i	17108
@NP	a dorsal view	17111
@NP	the animal	17141
@NP	-LRB- ii -RRB- an anterior view of the whole animal	17153
@NP	an anterior view	17158
@NP	the whole animal	17178
@NP	iii	17201
@NP	an anterior close-up of the right forelimb and head	17206
@NP	an anterior close-up	17206
@NP	the right forelimb and head	17230
@NP	Each of the movements involved in forelimb reaching	17259
@NP	Each	17259
@NP	the movements involved in forelimb reaching	17267
@NP	the movements	17267
@NP	forelimb reaching	17293
@NP	forelimb	17293
@NP	the Eshkol -- Wachman movement notation -LRB- Whishaw et al. , 1993 -RRB-	17326
@NP	the Eshkol -- Wachman movement notation	17326
@NP	Wachman	17337
@NP	Whishaw	17364
@NP	et al. , 1993	17372
@NP	et al.	17372
@NP	1993	17380
@NP	Anterograde CST	17387
@NP	the conclusion of behavioural experiments	17421
@NP	the conclusion	17421
@NP	behavioural experiments	17439
@NP	the 24 rats	17464
@NP	halothane -LRB- Rhone-Poulenc Chemicals Pty Ltd , Australia -RRB-	17500
@NP	halothane	17500
@NP	Rhone-Poulenc Chemicals Pty Ltd	17511
@NP	Australia	17544
@NP	an incision	17559
@NP	the skin covering the skull	17588
@NP	the skin	17588
@NP	the skull	17606
@NP	Two elongated craniotomies	17617
@NP	Two	17617
@NP	craniotomies	17631
@NP	5 mm	17657
@NP	either side of the midline from -7.1 mm bregma to + 2.9 mm lambda	17662
@NP	either side of the midline from -7.1 mm bregma to	17662
@NP	either side	17662
@NP	the midline from -7.1 mm bregma	17677
@NP	the midline	17677
@NP	-7.1 mm bregma	17694
@NP	2.9 mm lambda	17714
@NP	Anterograde tracer	17729
@NP	dextran amine	17761
@NP	BDA , 10 % in 2 ml of dH2O ; Molecular Probes , USA	17776
@NP	BDA	17776
@NP	10 % in 2 ml of dH2O ; Molecular Probes	17781
@NP	10 % in 2 ml of dH2O	17781
@NP	10 %	17781
@NP	2 ml of dH2O	17788
@NP	2 ml	17788
@NP	dH2O	17796
@NP	Molecular Probes	17802
@NP	USA	17820
@NP	these holes in three oblique injections	17846
@NP	these holes	17846
@NP	three oblique injections	17861
@NP	the sensorimotor cortex in each hemisphere using a Hamilton syringe	17891
@NP	the sensorimotor cortex	17891
@NP	each hemisphere using a Hamilton syringe	17918
@NP	each hemisphere	17918
@NP	a Hamilton syringe	17940
@NP	BDA conjugated with Texas red -LRB- BDA-R -RRB-	17960
@NP	BDA	17960
@NP	Texas red	17980
@NP	BDA-R	17991
@NP	the right cerebral cortex , ipsilateral	18016
@NP	the right cerebral cortex	18016
@NP	ipsilateral	18043
@NP	the spinal cord lesion	18058
@NP	BDA conjugated with fluorescein -LRB- BDA-G -RRB-	18090
@NP	BDA	18090
@NP	fluorescein	18110
@NP	BDA-G	18123
@NP	the left cortex , contralateral	18148
@NP	the left cortex	18148
@NP	contralateral	18165
@NP	the lesion site	18182
@NP	Perfusion and tissue processing	18199
@NP	Perfusion	18199
@NP	tissue processing	18213
@NP	Ten days	18231
@NP	cortical tracer injections	18246
@NP	animals	18274
@NP	0.8 ml	18313
@NP	Nembutal	18323
@NP	intraperitoneal , pentobarbitone sodium , 60 mg/ml ; Rhone Merieux , Australia	18333
@NP	intraperitoneal , pentobarbitone sodium	18333
@NP	60 mg/ml ; Rhone Merieux	18373
@NP	60 mg/ml	18373
@NP	Rhone Merieux	18383
@NP	Australia	18398
@NP	100 ml of heparinized Dulbecco 's phosphatebuffered saline wash	18442
@NP	100 ml	18442
@NP	heparinized Dulbecco 's phosphatebuffered saline wash	18452
@NP	heparinized Dulbecco 's	18452
@NP	100 ml of 4 % paraformaldehyde in Sorenson 's buffer , pH 7.4	18518
@NP	100 ml	18518
@NP	4 % paraformaldehyde in Sorenson 's buffer , pH 7.4	18528
@NP	4 % paraformaldehyde	18528
@NP	Sorenson 's buffer , pH 7.4	18551
@NP	Sorenson 's buffer	18551
@NP	Sorenson 's	18551
@NP	pH 7.4	18570
@NP	The head and vertebral column	18578
@NP	The head	18578
@NP	vertebral column	18591
@NP	each animal	18628
@NP	24 h.	18659
@NP	The brain and spinal cord	18665
@NP	The brain	18665
@NP	spinal cord	18679
@NP	the skull and vertebra	18711
@NP	intact in 0.1 M phosphate buffer -LRB- PB , pH 7.4 -RRB-	18745
@NP	intact in 0.1 M phosphate buffer	18745
@NP	0.1 M	18755
@NP	PB	18779
@NP	pH 7.4	18783
@NP	The position of the injury in the spinal cord	18792
@NP	The position	18792
@NP	the injury in the spinal cord	18808
@NP	the injury	18808
@NP	the spinal cord	18822
@NP	the caudal edge of the cerebellum	18856
@NP	the caudal edge	18856
@NP	the cerebellum	18875
@NP	all animals	18906
@NP	the same level	18935
@NP	A 2 cm segment	18951
@NP	the spinal cord	18979
@NP	the lesion at the mid-point of this segment	19001
@NP	the lesion	19001
@NP	the mid-point of this segment	19015
@NP	the mid-point	19015
@NP	this segment	19032
@NP	gelatine	19062
@NP	The embedded spinal cords	19072
@NP	40 mm thickness	19125
@NP	a CO2-freezing microtome -LRB- Polycut , Reichert-Jung , Australia -RRB-	19145
@NP	a CO2-freezing microtome	19145
@NP	Polycut	19171
@NP	Reichert-Jung	19180
@NP	Australia	19195
@NP	Consecutive series of sections	19207
@NP	Consecutive series	19207
@NP	sections	19229
@NP	24-well plates	19258
@NP	0.1 M PB	19284
@NP	0.01 % sodium azide -LRB- Sigma -RRB-	19298
@NP	0.01 % sodium azide	19298
@NP	Sigma	19318
@NP	4 °C	19340
@NP	immunohistochemistry	19364
@NP	Histology Twenty-one of the 24 cortically injected animals	19386
@NP	Histology Twenty-one	19386
@NP	the 24	19410
@NP	animals	19437
@NP	BDA tracer	19477
@NP	these 21 animals , one -LRB- OEG-NT-3 - transplanted -RRB-	19496
@NP	these 21 animals	19496
@NP	one -LRB- OEG-NT-3 - transplanted -RRB-	19514
@NP	one	19514
@NP	OEG-NT-3 - transplanted	19519
@NP	OEG-NT-3	19519
@NP	rat	19543
@NP	an incomplete lesion	19576
@NP	the relatively large numbers	19605
@NP	BDA-G-labelled fibres	19647
@NP	the damaged area	19691
@NP	one area	19739
@NP	a straight parallel bundle reminiscent of the intact anatomical projection	19765
@NP	a straight parallel bundle reminiscent	19765
@NP	the intact anatomical projection	19807
@NP	axon terminations	19854
@NP	the distal grey matter of the spinal cord segment	19893
@NP	the distal grey matter	19893
@NP	the spinal cord segment	19919
@NP	this animal	19944
@NP	further histological analysis	19974
@NP	sectioning	20011
@NP	the first complete spinal cord section	20023
@NP	the number 1	20075
@NP	this	20089
@NP	the lateral right-most part of the spinal cord	20100
@NP	the lateral right-most part	20100
@NP	the spinal cord	20131
@NP	Approximately 50 sections	20148
@NP	spinal cord	20193
@NP	Every eighth section on the lesioned side	20206
@NP	Every eighth section	20206
@NP	the lesioned side	20230
@NP	GFAP	20270
@NP	reactive astrocytes	20288
@NP	the lesion area	20311
@NP	Sections	20328
@NP	these	20349
@NP	p75	20378
@NP	a surface receptor	20383
@NP	the vast majority of OEG	20436
@NP	the vast majority	20436
@NP	OEG	20457
@NP	their transplantation	20467
@NP	injured spinal cord -LRB- Ruitenberg et al. , 2002a -RRB-	20494
@NP	injured spinal cord	20494
@NP	Ruitenberg	20515
@NP	et al. , 2002a	20526
@NP	et al.	20526
@NP	2002a	20534
@NP	Fluorophore-conjugated secondary antibodies	20542
@NP	labelled cells	20609
@NP	The immunohistochemical procedures	20625
@NP	GFAP and p75 staining on lesioned spinal cord tissue	20664
@NP	GFAP and p75 staining	20664
@NP	lesioned spinal cord tissue	20689
@NP	Ruitenberg	20744
@NP	et al. , 2002a , 2003	20755
@NP	et al.	20755
@NP	2002a	20763
@NP	2003	20770
@NP	Quantification of BDA-labelled CST axons	20777
@NP	Quantification	20777
@NP	BDA-labelled CST axons	20795
@NP	All sagittal sections	20818
@NP	BDA-G-labelled axons	20855
@NP	low magnification -LRB- x4 objective -RRB-	20904
@NP	low magnification	20904
@NP	x4 objective	20923
@NP	a BioRad MRC-1000	20943
@NP	confocal laser-scanning microscope attached to a Nikon Optiphot-2 microscope	20961
@NP	confocal laser-scanning microscope	20961
@NP	a Nikon Optiphot-2 microscope	21008
@NP	Centre for Microscopy and Microanalysis , UWA	21039
@NP	Centre	21039
@NP	Microscopy and Microanalysis	21050
@NP	UWA	21080
@NP	Quantitative comparisons of BDA-G-labelled axons	21086
@NP	Quantitative comparisons	21086
@NP	BDA-G-labelled axons	21114
@NP	the level of fluorescence	21149
@NP	the level	21149
@NP	fluorescence	21162
@NP	each section	21178
@NP	a computerized image analysis program	21198
@NP	ImageSpace , Molecular Dynamics	21237
@NP	ImageSpace	21237
@NP	Molecular Dynamics	21249
@NP	background and non-specific staining in each image	21270
@NP	background and non-specific staining	21270
@NP	each image	21310
@NP	the intensity thresholds	21346
@NP	The length and density of BDA-G-labelled axons across the lesion	21372
@NP	The length and density	21372
@NP	BDA-G-labelled axons across the lesion	21398
@NP	BDA-G-labelled axons	21398
@NP	the lesion	21426
@NP	measurements	21463
@NP	four distances -LRB- Fig. 5A and B -RRB-	21479
@NP	four distances	21479
@NP	Fig. 5A and B	21495
@NP	Fig. 5A	21495
@NP	B	21507
@NP	1 mm proximal to the middle of the lesion site -LRB- -1 mm -RRB-	21511
@NP	1 mm proximal to the middle of the lesion site	21511
@NP	1 mm	21511
@NP	the middle of the lesion site	21528
@NP	the middle	21528
@NP	the lesion site	21542
@NP	-1 mm	21559
@NP	the middle of the lesion -LRB- 0 mm -RRB-	21567
@NP	the middle	21567
@NP	the lesion -LRB- 0 mm -RRB-	21581
@NP	the lesion	21581
@NP	0 mm	21593
@NP	0.5 mm	21600
@NP	the middle of the lesion -LRB- + 0.5 mm -RRB-	21617
@NP	the middle	21617
@NP	the lesion -LRB- + 0.5 mm -RRB-	21631
@NP	the lesion	21631
@NP	+	21644
@NP	0.5 mm	21646
@NP	0.5	21646
@NP	mm	21650
@NP	1 mm	21658
@NP	the middle -LRB- + 1.0 mm -RRB-	21673
@NP	the middle	21673
@NP	+	21685
@NP	1.0 mm	21687
@NP	1.0	21687
@NP	mm	21691
@NP	each distance	21699
@NP	a measure of fluorescence	21714
@NP	a measure	21714
@NP	fluorescence	21727
@NP	number of pixels within the altered thresholds x average pixel intensity	21754
@NP	number	21754
@NP	pixels within the altered thresholds x average pixel intensity	21764
@NP	pixels	21764
@NP	the altered thresholds x average pixel intensity	21778
@NP	the altered thresholds	21778
@NP	average pixel intensity	21803
@NP	The initial adjustment of intensity thresholds	21829
@NP	The initial adjustment	21829
@NP	intensity thresholds	21855
@NP	all background signal	21903
@NP	each image	21930
@NP	this	21957
@NP	measurements from three areas of ventral white matter	21963
@NP	measurements	21963
@NP	three areas of ventral white matter	21981
@NP	three areas	21981
@NP	ventral white matter	21996
@NP	representative of background staining	22018
@NP	representative	22018
@NP	background staining	22036
@NP	a value	22079
@NP	background fluorescence	22091
@NP	signal fluorescence	22147
@NP	the four distances across the lesion site	22170
@NP	the four distances	22170
@NP	the lesion site	22196
@NP	addition to the quantitative analysis in sagittal sections	22216
@NP	addition	22216
@NP	the quantitative analysis in sagittal sections	22228
@NP	the quantitative analysis	22228
@NP	sagittal sections	22257
@NP	additional analysis of signal fluorescence in the lesioned CST projection	22276
@NP	additional analysis	22276
@NP	signal fluorescence in the lesioned CST projection	22299
@NP	signal fluorescence	22299
@NP	the lesioned CST projection	22322
@NP	transverse sections -LRB- 40 mm -RRB-	22367
@NP	transverse sections	22367
@NP	40 mm	22388
@NP	1 cm proximal	22403
@NP	1 cm	22403
@NP	1 cm distal from the lesion epicentre	22424
@NP	1 cm	22424
@NP	the lesion epicentre	22441
@NP	Digital images	22463
@NP	a free form profile measurement tool	22512
@NP	the labelled and non-labelled areas	22562
@NP	The intensity of fluorescence	22599
@NP	The intensity	22599
@NP	fluorescence	22616
@NP	1 cm proximal and 1 cm distal	22650
@NP	1 cm	22650
@NP	1 cm	22668
@NP	a percentage label	22699
@NP	Background fluorescence	22719
@NP	the final value	22763
@NP	Assessment	22801
@NP	spinal tissue sparing Every fourth sagittal section from the spinal cord	22815
@NP	spinal tissue	22815
@NP	Every fourth sagittal section	22837
@NP	the spinal cord	22872
@NP	the volume of spared tissue -LRB- Plant et al. , 2003 -RRB-	22910
@NP	the volume	22910
@NP	spared tissue -LRB- Plant et al. , 2003 -RRB-	22924
@NP	spared tissue	22924
@NP	Plant	22939
@NP	et al. , 2003	22945
@NP	et al.	22945
@NP	2003	22953
@NP	The analysis	22960
@NP	five rats	22990
@NP	each of the mediuminjected or OEG -	23005
@NP	each	23005
@NP	the mediuminjected or OEG -	23013
@NP	the mediuminjected	23013
@NP	OEG	23035
@NP	OEG-LacZ - and OEG-NT-3-implanted groups	23041
@NP	OEG-LacZ	23041
@NP	OEG-NT-3-implanted groups	23055
@NP	each section	23085
@NP	the pixel number	23099
@NP	the damaged area	23119
@NP	the total number of pixels in a 2.5 mm long spinal cord segment	23140
@NP	the total number	23140
@NP	pixels in a 2.5 mm long spinal cord segment	23160
@NP	pixels	23160
@NP	a 2.5 mm	23170
@NP	spinal cord segment	23184
@NP	the lesion epicentre in the middle	23210
@NP	the lesion epicentre	23210
@NP	the middle	23234
@NP	The border of the damaged area	23260
@NP	The border	23260
@NP	the damaged area	23274
@NP	an obvious discontinuity in the density of small cells , i.e.	23306
@NP	an obvious discontinuity	23306
@NP	the density of small cells	23334
@NP	the density	23334
@NP	small cells	23349
@NP	transplanted cells and inflammatory cells	23367
@NP	transplanted cells	23367
@NP	inflammatory cells	23390
@NP	the absence of healthy looking spinal neurons	23414
@NP	the absence	23414
@NP	healthy looking spinal neurons	23429
@NP	This area	23461
@NP	the grafted cells and usually some small cysts	23481
@NP	the grafted cells	23481
@NP	usually some small cysts	23503
@NP	Measurements from each section	23529
@NP	Measurements	23529
@NP	each section	23547
@NP	rat	23576
@NP	the total number of sections	23598
@NP	the total number	23598
@NP	sections	23618
@NP	spinal tissue	23635
@NP	the difference	23670
@NP	the number	23693
@NP	pixels	23707
@NP	the area	23717
@NP	damaged tissue -LRB- cyst area and degenerate area -RRB-	23729
@NP	damaged tissue	23729
@NP	cyst area and degenerate area	23745
@NP	cyst area	23745
@NP	degenerate area	23759
@NP	the number of pixels in the whole segment	23780
@NP	the number	23780
@NP	pixels in the whole segment	23794
@NP	pixels	23794
@NP	the whole segment	23804
@NP	Similar methods	23823
@NP	graft size	23864
@NP	p75-stained sections	23882
@NP	there	23907
@NP	a concordance	23916
@NP	p75 staining and OEG viability	23938
@NP	up to 4 months after transplantation -LRB- Ruitenberg et al. , 2002a -RRB-	23973
@NP	up to 4 months	23973
@NP	transplantation -LRB- Ruitenberg et al. , 2002a -RRB-	23994
@NP	transplantation	23994
@NP	Ruitenberg	24011
@NP	et al. , 2002a	24022
@NP	et al.	24022
@NP	2002a	24030
@NP	The relative amount of degenerate tissue	24038
@NP	The relative amount	24038
@NP	degenerate tissue	24061
@NP	the number of pixels in the p75-positive area	24114
@NP	the number	24114
@NP	pixels in the p75-positive area	24128
@NP	pixels	24128
@NP	the p75-positive area	24138
@NP	the total pixel number of the damaged area	24165
@NP	the total pixel number	24165
@NP	the damaged area	24191
@NP	Statistical analysis All statistical analysis	24209
@NP	Statistical analysis	24209
@NP	All statistical analysis	24230
@NP	standard statistics computer software -LRB- SPSS for Windows , Release 10 -RRB-	24272
@NP	standard statistics computer software	24272
@NP	SPSS for Windows , Release 10	24311
@NP	SPSS	24311
@NP	Windows	24320
@NP	Release 10	24329
@NP	Data sets	24342
@NP	significance	24370
@NP	one-way and repeated measures ANOVA -LRB- analysis of variance -RRB-	24389
@NP	one-way and repeated measures	24389
@NP	ANOVA -LRB- analysis of variance -RRB-	24419
@NP	ANOVA	24419
@NP	analysis of variance	24426
@NP	analysis	24426
@NP	variance	24438
@NP	simple contrast tests	24451
@NP	All data	24474
@NP	means = SEM	24503
@NP	Fig. 5C , which shows means 6 SD to better visualize intra-group variation	24525
@NP	Fig. 5C	24525
@NP	6 SD	24552
@NP	intra-group variation	24577
@NP	Results	24601
@NP	Fig. 1 In vitro and in vivo analysis	24609
@NP	Fig. 1	24609
@NP	In vitro and in vivo analysis	24616
@NP	vivo	24632
@NP	AdV vector-mediated transgene expression	24649
@NP	-LRB- A -RRB- X-Gal cytochemistry of primary OEG	24691
@NP	-LRB- A -RRB- X-Gal cytochemistry	24691
@NP	A	24692
@NP	primary OEG	24718
@NP	72 h after transduction with AdV-LacZ vector	24731
@NP	72 h	24731
@NP	transduction with AdV-LacZ vector	24742
@NP	transduction	24742
@NP	AdV-LacZ vector	24760
@NP	Virtually all cultured cells	24777
@NP	Virtually all	24777
@NP	cells	24800
@NP	the LacZ gene product	24816
@NP	-LRB- B -RRB-	24839
@NP	a cRNA probe	24849
@NP	NT-3 mRNA , cells transduced with AdV-NT-3 vector	24875
@NP	NT-3 mRNA	24875
@NP	cells transduced with AdV-NT-3 vector	24886
@NP	cells	24886
@NP	AdV-NT-3 vector	24908
@NP	high levels of this neurotrophin	24934
@NP	high levels	24934
@NP	this neurotrophin	24949
@NP	72 h	24973
@NP	-LRB- C -RRB- Conditioned medium from AdV-NT-3 vector-transduced OEG cells	24988
@NP	-LRB- C -RRB- Conditioned medium	24988
@NP	C	24989
@NP	AdV-NT-3 vector-transduced OEG cells	25016
@NP	E15 dorsal root ganglion -LRB- DRG -RRB-	25066
@NP	E15 dorsal root ganglion	25066
@NP	DRG	25092
@NP	cultures and neurite outgrowth	25097
@NP	cultures	25097
@NP	neurite outgrowth	25110
@NP	48 h.	25157
@NP	AdV vector-derived NT-3 in OEG conditioned medium	25163
@NP	AdV vector-derived NT-3	25163
@NP	OEG conditioned medium	25190
@NP	the induction of robust neurite growth	25257
@NP	the induction	25257
@NP	robust neurite growth	25274
@NP	DRG explants	25310
@NP	-LRB- D -RRB- Higher magnification of the outlined area	25324
@NP	Higher magnification	25328
@NP	the outlined area	25352
@NP	C showing neurite extensions with growth cone-like structures	25373
@NP	C	25373
@NP	neurite extensions	25383
@NP	growth cone-like structures	25407
@NP	-LRB- E -RRB- Conditioned medium taken from control	25436
@NP	-LRB- E -RRB- Conditioned medium	25436
@NP	E	25437
@NP	control	25470
@NP	OEG-LacZ	25479
@NP	cultures	25489
@NP	very little outgrowth	25506
@NP	DRG explants	25533
@NP	-LRB- F -RRB-	25547
@NP	In vivo confirmation of AdV	25551
@NP	In vivo confirmation	25551
@NP	AdV	25575
@NP	vector-mediated NT-3 expression at 7 days after injection of AdV-NT-3	25579
@NP	vector-mediated NT-3 expression	25579
@NP	7 days after injection of AdV-NT-3	25614
@NP	7 days	25614
@NP	injection of AdV-NT-3	25627
@NP	injection	25627
@NP	AdV-NT-3	25640
@NP	vector-transduced OEG suspensions into the lesioned spinal cord	25649
@NP	vector-transduced OEG suspensions	25649
@NP	the lesioned spinal cord	25688
@NP	Scale bars : A , B = 83 µm ; C , E = 1 mm ; D = 275 µm ; F = 170 µm .	25714
@NP	Scale bars	25714
@NP	A , B = 83 µm	25726
@NP	A	25726
@NP	B = 83 µm	25729
@NP	B	25729
@NP	= 83 µm	25731
@NP	83	25733
@NP	C , E = 1 mm	25740
@NP	C	25740
@NP	E = 1 mm	25743
@NP	E	25743
@NP	= 1 mm	25745
@NP	1	25747
@NP	D = 275 µm	25753
@NP	D	25753
@NP	= 275 µm	25755
@NP	275	25757
@NP	F = 170 µm	25765
@NP	F	25765
@NP	= 170 µm	25767
@NP	170	25769
@NP	Fig. 2 Behavioural assessment of forepaw function in experimental animals .	25778
@NP	Fig.	25778
@NP	2 Behavioural assessment of forepaw function in experimental animals	25783
@NP	2 Behavioural assessment	25783
@NP	forepaw function in experimental animals	25811
@NP	forepaw function	25811
@NP	experimental animals	25831
@NP	-LRB- A -RRB- Pre-surgery skilled forepaw movements	25853
@NP	-LRB- A -RRB-	25853
@NP	Pre-surgery skilled forepaw movements	25857
@NP	experimental rats	25910
@NP	All animals	25929
@NP	the opening with their right forepaw	25983
@NP	the opening	25983
@NP	their right forepaw	26000
@NP	they	26021
@NP	the food pellet	26034
@NP	it	26081
@NP	their mouth	26087
@NP	3 weeks after the surgery	26103
@NP	3 weeks	26103
@NP	the surgery	26117
@NP	pellet retrieval	26130
@NP	all experimental animals , i.e. the lesioned forepaw was paralysed	26172
@NP	all experimental animals	26172
@NP	i.e. the lesioned forepaw was paralysed	26198
@NP	i.e.	26198
@NP	the lesioned forepaw	26203
@NP	the rats	26242
@NP	the skilled reaches that are required to grab the food pellet reward	26278
@NP	the skilled reaches	26278
@NP	the food pellet reward	26324
@NP	12 weeks after surgery	26351
@NP	12 weeks	26351
@NP	surgery	26366
@NP	success ratings in pellet retrieval	26375
@NP	success ratings	26375
@NP	pellet retrieval	26394
@NP	all experimental groups	26444
@NP	further analysis	26473
@NP	there	26502
@NP	no concurrent improvement in Eshkol	26512
@NP	no concurrent improvement	26512
@NP	Eshkol	26541
@NP	Wachman movement notation for the impaired forepaw	26548
@NP	Wachman movement notation	26548
@NP	the impaired forepaw	26578
@NP	The animals	26600
@NP	partial forepaw paralysis	26627
@NP	the head and shoulders	26664
@NP	an anti-clockwise motion almost 90 ° , such	26690
@NP	an anti-clockwise motion	26690
@NP	almost 90 °	26715
@NP	the lesioned forelimb	26737
@NP	the air	26773
@NP	This forepaw	26782
@NP	the food pellet	26818
@NP	the limb	26838
@NP	it	26870
@NP	the animals mouth as illustrated	26878
@NP	the animals mouth	26878
@NP	illustrated	26899
@NP	Components such as grasp , supination and release	26912
@NP	Components	26912
@NP	grasp , supination and release	26931
@NP	-LRB- B -RRB- Weekly averages of success ratings , i.e.	26984
@NP	-LRB- B -RRB-	26984
@NP	Weekly averages of success ratings , i.e.	26988
@NP	Weekly averages	26988
@NP	success ratings	27007
@NP	the number of pellets	27029
@NP	the number	27029
@NP	pellets	27043
@NP	2 min time interval	27065
@NP	each of the four groups before lesioning and during the testing period	27090
@NP	each	27090
@NP	the four groups before lesioning and during the testing period	27098
@NP	the four groups	27098
@NP	the testing period	27142
@NP	the -LRB- spontaneous -RRB- improvement	27167
@NP	spontaneous	27172
@NP	that	27197
@NP	time in all groups	27220
@NP	time	27220
@NP	all groups	27228
@NP	-LRB- C -RRB- Weekly averages of Eshkol	27240
@NP	Weekly averages	27244
@NP	Eshkol	27263
@NP	Wachman movement notation	27270
@NP	Wachman	27270
@NP	movement notation	27278
@NP	rating of skilled forelimb use	27302
@NP	rating	27302
@NP	skilled forelimb use	27312
@NP	each of the four groups	27338
@NP	each	27338
@NP	the four groups	27346
@NP	-LRB- D -RRB-	27372
@NP	` Success versus movement ' analysis	27376
@NP	movement	27392
@NP	an individual animal	27414
@NP	that animal 11	27518
@NP	a simultaneous improvement	27546
@NP	pellet retrieval success and forelimb movement rating from week 7	27576
@NP	pellet retrieval success and forelimb movement rating	27576
@NP	week 7	27635
@NP	9	27645
@NP	no such parallel recovery	27656
@NP	animal 18	27698
@NP	Fig. 3 Graphic	27710
@NP	representation and confocal photomicrographs of dual-coloured anterograde	27725
@NP	representation and confocal photomicrographs	27725
@NP	dual-coloured anterograde	27773
@NP	CST in normal and spinal cord-injured animals	27799
@NP	CST	27799
@NP	normal and spinal cord-injured animals	27806
@NP	-LRB- A -RRB- Schematic diagram	27846
@NP	A	27847
@NP	the tracer injection sites and subsequent labelling	27871
@NP	the tracer injection	27871
@NP	the different sensorimotor	27926
@NP	cortical hemispheres and CST projections	27953
@NP	cortical hemispheres	27953
@NP	CST projections	27978
@NP	-LRB- B -RRB- Representative horizontal spinal cord section showing the two	27995
@NP	-LRB- B -RRB- Representative horizontal spinal cord section	27995
@NP	-LRB- B -RRB-	27995
@NP	Representative horizontal spinal cord section	27999
@NP	the two	28053
@NP	CST projections	28083
@NP	an uninjured control animal	28102
@NP	-LRB- C -RRB- Transverse section through the cervical -LRB- C4 -RRB- spinal cord	28131
@NP	-LRB- C -RRB- Transverse section	28131
@NP	C	28132
@NP	the cervical -LRB- C4 -RRB- spinal cord	28162
@NP	C4	28176
@NP	the dorsal column region	28201
@NP	CST projections	28239
@NP	the distinct labelling of axons within both CST projections	28261
@NP	the distinct labelling	28261
@NP	axons within both CST projections	28287
@NP	axons	28287
@NP	both CST projections	28300
@NP	Only occasional BDA-G-positive fibres	28322
@NP	the BDA-R-labelled CST	28373
@NP	vice	28401
@NP	Representative confocal photomicrograph	28417
@NP	an OEG-LacZ transplanted rat , 12 weeks post-surgery , showing successfully	28460
@NP	an OEG-LacZ transplanted rat , 12 weeks post-surgery ,	28460
@NP	an OEG-LacZ transplanted rat	28460
@NP	12 weeks post-surgery	28490
@NP	BDA-G-labelled	28544
@NP	CST axons	28560
@NP	the BDA-R-labelled CST	28576
@NP	Lesioned CST axons	28617
@NP	enlarged , bulbous ends	28650
@NP	large fibre masses	28678
@NP	the rostral edge of the lesion site	28721
@NP	the rostral edge	28721
@NP	the lesion site	28741
@NP	Virtually no regrowth of lesioned CST axons	28758
@NP	Virtually no regrowth	28758
@NP	lesioned CST axons	28783
@NP	animals receiving control -LRB- OEG and OEG-LacZ -RRB- implants	28817
@NP	animals	28817
@NP	control -LRB- OEG and OEG-LacZ -RRB-	28835
@NP	control	28835
@NP	OEG and OEG-LacZ	28844
@NP	OEG	28844
@NP	OEG-LacZ	28852
@NP	implants	28862
@NP	-LRB- E -RRB- Consecutive section	28872
@NP	-LRB- E -RRB-	28872
@NP	Consecutive section	28876
@NP	GFAP-positive hyperactive astrocytes	28904
@NP	the lesion and implantation site	28953
@NP	cc = central canal ; gm = grey matter ; wm = white matter .	28987
@NP	cc = central canal	28987
@NP	cc	28987
@NP	= central canal	28990
@NP	gm = grey matter	29007
@NP	gm	29007
@NP	= grey matter	29010
@NP	wm = white matter	29025
@NP	wm	29025
@NP	= white matter	29028
@NP	Scale bars : B = 374 µm ; C = 178 µm ; D , E = 227 µm .	29044
@NP	Scale bars	29044
@NP	B = 374 µm	29056
@NP	B	29056
@NP	= 374 µm	29058
@NP	C = 178 µm	29068
@NP	C	29068
@NP	= 178 µm	29070
@NP	178	29072
@NP	D , E = 227 µm	29080
@NP	D	29080
@NP	E = 227 µm	29083
@NP	E	29083
@NP	= 227 µm	29085
@NP	Fig. 4 Transplant purity and distal CST axons in OEG-NT-3-transplanted rats .	29096
@NP	Fig.	29096
@NP	4 Transplant purity and distal CST axons	29101
@NP	4 Transplant purity	29101
@NP	distal CST axons	29125
@NP	OEG-NT-3-transplanted rats	29145
@NP	-LRB- A -RRB-	29173
@NP	immunopanning	29183
@NP	primary OEG cultures for transplantation purposes	29198
@NP	primary OEG cultures	29198
@NP	transplantation purposes	29223
@NP	p75-positive -LRB- red -RRB- cells and between 95 and 98 % pure	29265
@NP	p75-positive -LRB- red -RRB- cells	29265
@NP	between 95 and 98 % pure	29294
@NP	the ratio of p75-positive cells and the total number of Hoechst	29337
@NP	the ratio of p75-positive cells	29337
@NP	the ratio	29337
@NP	p75-positive cells	29350
@NP	the total number of Hoechst	29373
@NP	the total number	29373
@NP	Hoechst	29393
@NP	dye-positive -LRB- blue -RRB- nuclei	29401
@NP	OEG	29438
@NP	GFAP -LRB- green -RRB-	29471
@NP	GFAP	29471
@NP	-LRB- B -RRB- Representative image	29485
@NP	B	29486
@NP	intense p75 immunoreactivity -LRB- asterisk -RRB-	29513
@NP	intense p75 immunoreactivity	29513
@NP	asterisk	29543
@NP	the lesion and implantation site	29556
@NP	12 weeks after surgery	29590
@NP	12 weeks	29590
@NP	surgery	29605
@NP	OEG-transplanted animals only	29629
@NP	OEG-transplanted animals	29629
@NP	Low-power micrograph	29664
@NP	a typical OEG-NT-3-transplanted rat at 12 weeks after surgery	29688
@NP	a typical OEG-NT-3-transplanted rat	29688
@NP	12 weeks after surgery	29727
@NP	12 weeks	29727
@NP	surgery	29742
@NP	Distal BDA-G-labelled CST axons -LRB- arrows -RRB-	29751
@NP	Distal BDA-G-labelled CST axons	29751
@NP	arrows	29784
@NP	the proximal mass -LRB- white line -RRB-	29806
@NP	the proximal mass	29806
@NP	white line	29825
@NP	the lesion area	29848
@NP	the more ventral portions	29872
@NP	1 cm distally	29932
@NP	1 cm	29932
@NP	Higher magnification	29951
@NP	the lesion and implantation area , -LRB- outlined by the dashed line -RRB-	29975
@NP	the lesion and implantation area ,	29975
@NP	the lesion	29975
@NP	implantation area	29990
@NP	the dashed line	30022
@NP	another OEG-NT-3-transplanted rat	30042
@NP	a significant number of BDA-G-labelled CST axons -LRB- arrows -RRB-	30084
@NP	a significant number	30084
@NP	BDA-G-labelled CST axons -LRB- arrows -RRB-	30108
@NP	BDA-G-labelled CST axons	30108
@NP	arrows	30134
@NP	the ventral portions of the damaged area	30151
@NP	the ventral portions	30151
@NP	the damaged area	30175
@NP	the opposing part of the spinal cord	30211
@NP	the opposing part	30211
@NP	the spinal cord	30232
@NP	-LRB- E -RRB- Transverse spinal cord section	30249
@NP	-LRB- E -RRB-	30249
@NP	Transverse spinal cord section	30253
@NP	1 cm distal to the C4 lesion site	30285
@NP	1 cm	30285
@NP	the C4 lesion site	30300
@NP	an OEG-LacZ-transplanted rat	30331
@NP	12 weeks	30363
@NP	surgery	30378
@NP	the presence	30392
@NP	BDA-R-positive axons in the intact CST projection -LRB- left -RRB-	30408
@NP	BDA-R-positive axons	30408
@NP	the intact CST projection -LRB- left -RRB-	30432
@NP	the intact CST projection	30432
@NP	left	30459
@NP	BDA-G-labelled axons	30473
@NP	the degenerated projection area	30508
@NP	the lesioned side of the spinal cord -LRB- dashed line -RRB-	30543
@NP	the lesioned side	30543
@NP	the spinal cord	30564
@NP	line	30588
@NP	the completeness of the injury	30609
@NP	the completeness	30609
@NP	the injury	30629
@NP	-LRB- F -RRB- Scattered BDA-G-labelled fibres	30641
@NP	-LRB- F -RRB-	30641
@NP	BDA-G-labelled fibres	30655
@NP	1 cm distal to the injury site in OEG-NT-3-transplanted animals	30690
@NP	1 cm	30690
@NP	the injury site in OEG-NT-3-transplanted animals	30705
@NP	the injury site	30705
@NP	OEG-NT-3-transplanted animals	30724
@NP	CST = corticospinal tract ; gm = grey matter ; wm = white matter .	30760
@NP	CST = corticospinal tract	30760
@NP	CST	30760
@NP	= corticospinal tract	30764
@NP	gm = grey matter	30787
@NP	gm	30787
@NP	= grey matter	30790
@NP	wm = white matter	30805
@NP	wm	30805
@NP	= white matter	30808
@NP	Scale bars : A = 41 µm ; B = 91 µm ; C = 870 µm ; D = 279 µm ; E , F = 71 µm .	30824
@NP	Scale bars	30824
@NP	A = 41 µm	30836
@NP	A	30836
@NP	= 41 µm	30838
@NP	41	30840
@NP	B = 91 µm	30847
@NP	B	30847
@NP	= 91 µm	30849
@NP	91	30851
@NP	C = 870 µm	30858
@NP	C	30858
@NP	= 870 µm	30860
@NP	870	30862
@NP	D = 279 µm	30870
@NP	D	30870
@NP	= 279 µm	30872
@NP	279	30874
@NP	E , F = 71 µm	30882
@NP	E	30882
@NP	F = 71 µm	30885
@NP	F	30885
@NP	= 71 µm	30887
@NP	71	30889
@NP	Fig.	30897
@NP	5 Quantitative analysis	30902
@NP	distal CST axons at 12 weeks after injury and OEG implantation	30929
@NP	distal CST axons	30929
@NP	12 weeks after injury and OEG implantation	30949
@NP	12 weeks	30949
@NP	injury and OEG implantation	30964
@NP	-LRB- A -RRB- Typical example	30993
@NP	A	30994
@NP	a confocal microscope image of an OEG-implanted animal	31016
@NP	a confocal microscope image	31016
@NP	an OEG-implanted animal	31047
@NP	a sagittal section	31080
@NP	the spinal cord with the lesion epicentre in the middle	31107
@NP	the spinal cord	31107
@NP	the lesion epicentre in the middle	31128
@NP	the lesion epicentre	31128
@NP	the middle	31152
@NP	-LRB- B -RRB-	31164
@NP	image	31178
@NP	A	31187
@NP	the computer	31206
@NP	fibre fluorescence	31231
@NP	image analysis software	31256
@NP	The position of the vertical bars	31281
@NP	The position	31281
@NP	the vertical bars	31297
@NP	the regions of analysis	31325
@NP	the regions	31325
@NP	analysis	31340
@NP	-LRB- C -RRB- Measurements of BDA-G-labelled axons at the lesion	31350
@NP	-LRB- C -RRB- Measurements	31350
@NP	C	31351
@NP	BDA-G-labelled axons at the lesion	31370
@NP	BDA-G-labelled axons	31370
@NP	the lesion	31394
@NP	site	31405
@NP	sagittal spinal cord sections from all experimental groups	31428
@NP	sagittal spinal cord sections	31428
@NP	all experimental groups	31463
@NP	pixels of fluorescence	31504
@NP	pixels	31504
@NP	fluorescence	31514
@NP	mean 6 SD	31528
@NP	mean	31528
@NP	6 SD	31533
@NP	There	31540
@NP	a trend	31550
@NP	increased numbers	31566
@NP	axons	31587
@NP	the more distal parts	31596
@NP	the lesion and implantation site in OEG-NT-3-implanted animals	31621
@NP	the lesion and implantation site	31621
@NP	OEG-NT-3-implanted animals	31657
@NP	Quantification	31689
@NP	BDA-G-traced CST axons	31707
@NP	transverse spinal cord sections , 1 cm distal to the injury site	31733
@NP	transverse spinal cord sections	31733
@NP	1 cm distal to the injury site	31766
@NP	1 cm	31766
@NP	the injury site	31781
@NP	The obtained measurements	31798
@NP	the percentage of total fluorescence	31841
@NP	the percentage	31841
@NP	total fluorescence	31859
@NP	1 cm proximal to the injury site	31881
@NP	1 cm	31881
@NP	the injury site	31898
@NP	variability	31932
@NP	efficiency of CST	31947
@NP	efficiency	31947
@NP	CST	31961
@NP	relative percentage of fluorescence intensity ± SEM	31974
@NP	relative percentage of fluorescence intensity	31974
@NP	relative percentage	31974
@NP	fluorescence intensity	31997
@NP	± SEM	32020
@NP	Significantly more distal BDA-G-labelled fibres	32028
@NP	OEG-NT-3-implanted rats	32093
@NP	all other experimental animal groups -LRB- P ≤ 0.0005 -RRB-	32131
@NP	all other experimental animal groups	32131
@NP	P ≤ 0.0005	32169
@NP	P	32169
@NP	≤ 0.0005	32171
@NP	Fig. 6 OEG implants	32183
@NP	Fig.	32183
@NP	6 OEG implants	32188
@NP	the spinal cord lesion size	32210
@NP	tissue	32251
@NP	-LRB- A -RRB- Statistical analysis	32259
@NP	-LRB- A -RRB-	32259
@NP	Statistical analysis	32263
@NP	the mean percentage of spared spinal tissue	32296
@NP	the mean percentage	32296
@NP	spared spinal tissue	32319
@NP	all OEG-transplanted animal groups	32369
@NP	vehicle-injected controls -LRB- P ≤ 0.006 -RRB-	32418
@NP	vehicle-injected controls	32418
@NP	P ≤ 0.006	32445
@NP	P	32445
@NP	≤ 0.006	32447
@NP	-LRB- B -RRB- No significant changes in total cyst number	32457
@NP	-LRB- B -RRB-	32457
@NP	No significant changes in total cyst number	32461
@NP	No significant changes	32461
@NP	total cyst number	32487
@NP	cystic -LRB- pixel -RRB- area	32509
@NP	pixel	32517
@NP	the different experimental groups	32547
@NP	-LRB- C -RRB-	32582
@NP	The area of degenerate tissue	32586
@NP	The area	32586
@NP	degenerate tissue	32598
@NP	all OEG-implanted animals	32645
@NP	the OEG-NT-3-transplanted animal group -LRB- P < 0.004 -RRB- -LRB- D -RRB-	32699
@NP	the OEG-NT-3-transplanted animal group -LRB- P < 0.004 -RRB-	32699
@NP	the OEG-NT-3-transplanted animal group	32699
@NP	P < 0.004	32739
@NP	P	32739
@NP	< 0.004	32741
@NP	<	32741
@NP	0.004	32743
@NP	D	32751
@NP	The p75-positive -LRB- pixel -RRB- area in the grafted region	32755
@NP	The p75-positive -LRB- pixel -RRB- area	32755
@NP	pixel	32773
@NP	the grafted region	32788
@NP	OEGand OEG-LacZ-transplanted rats	32835
@NP	implantation of AdV-NT-3-transduced OEG -LRB- P < 0.004 -RRB-	32906
@NP	implantation	32906
@NP	AdV-NT-3-transduced OEG -LRB- P < 0.004 -RRB-	32922
@NP	AdV-NT-3-transduced OEG	32922
@NP	P < 0.004	32947
@NP	P	32947
@NP	< 0.004	32949
@NP	<	32949
@NP	0.004	32951
@NP	A single asterisk	32959
@NP	statistical significance	32987
@NP	vehicle-injected lesioned control animals	33017
@NP	double asterisks	33068
@NP	significance of OEG-NT-3-transplanted rats	33093
@NP	significance	33093
@NP	OEG-NT-3-transplanted rats	33109
@NP	all other experimental groups	33150
@NP	Fig. 7	33182
@NP	In vitro analysis of mitogenic effects of NT-3	33189
@NP	In vitro analysis	33189
@NP	mitogenic effects of NT-3	33210
@NP	mitogenic effects	33210
@NP	NT-3	33231
@NP	adult OEG	33248
@NP	A and B	33260
@NP	A	33260
@NP	B	33266
@NP	Proliferation of	33269
@NP	Proliferation	33269
@NP	adult OEG	33295
@NP	the rat olfactory bulb nerve layer , in DF-10S medium	33320
@NP	the rat	33320
@NP	bulb nerve layer , in DF-10S medium	33338
@NP	bulb nerve layer	33338
@NP	the absence -LRB- A -RRB- and presence of NT-3 -LRB- B ; 50 ng/ml -RRB-	33376
@NP	the absence -LRB- A -RRB-	33376
@NP	the absence	33376
@NP	A	33389
@NP	presence of NT-3 -LRB- B ; 50 ng/ml -RRB-	33396
@NP	presence	33396
@NP	NT-3 -LRB- B ; 50 ng/ml -RRB-	33408
@NP	NT-3	33408
@NP	B ; 50 ng/ml	33414
@NP	B	33414
@NP	50 ng/ml	33417
@NP	Cultures	33428
@NP	S100 -LRB- green -RRB- , BrdU -LRB- red -RRB- and Hoechst dye -LRB- blue -RRB-	33461
@NP	S100 -LRB- green -RRB-	33461
@NP	S100	33461
@NP	BrdU -LRB- red -RRB- and Hoechst dye -LRB- blue -RRB-	33475
@NP	BrdU -LRB- red -RRB-	33475
@NP	BrdU	33475
@NP	red	33481
@NP	Hoechst dye -LRB- blue -RRB-	33490
@NP	Hoechst	33490
@NP	proliferating cells	33513
@NP	the nuclear co-localization of BrdU signal and Hoechst	33534
@NP	the nuclear co-localization	33534
@NP	BrdU signal and Hoechst	33565
@NP	BrdU signal	33565
@NP	Hoechst	33581
@NP	results in a purple nuclear	33593
@NP	results	33593
@NP	a purple nuclear	33604
@NP	-LRB- C -RRB- Quantitative analysis of OEG proliferation	33628
@NP	-LRB- C -RRB- Quantitative analysis	33628
@NP	C	33629
@NP	OEG proliferation	33657
@NP	cells	33681
@NP	CD - or DF-10S medium , containing various amounts of NT-3 ,	33713
@NP	CD - or DF-10S medium	33713
@NP	various amounts of NT-3	33746
@NP	various amounts	33746
@NP	NT-3	33765
@NP	AdV-NT-3	33790
@NP	the percentage of proliferating cells	33813
@NP	the percentage	33813
@NP	proliferating cells	33831
@NP	medium	33869
@NP	no serum , pituitary extract and forskolin	33888
@NP	no serum	33888
@NP	pituitary extract	33898
@NP	forskolin	33920
@NP	No evidence	33931
@NP	NT-3	33958
@NP	cells	33995
@NP	recombinant protein	34013
@NP	the culture medium	34036
@NP	a mitogenic effect on OEG -LRB- P > 0.05 -RRB-	34060
@NP	a mitogenic effect	34060
@NP	OEG -LRB- P > 0.05 -RRB-	34082
@NP	OEG	34082
@NP	P > 0.05	34087
@NP	P	34087
@NP	> 0.05	34089
@NP	>	34089
@NP	0.05	34091
@NP	D and E -RRB- Confirmation	34099
@NP	the biological activity of recombinant NT-3	34124
@NP	the biological activity	34124
@NP	recombinant NT-3	34151
@NP	E15 DRG explants	34169
@NP	pan-neurofilament -LRB- green -RRB- , S100 protein -LRB- red -RRB-	34213
@NP	pan-neurofilament -LRB- green -RRB-	34213
@NP	pan-neurofilament	34213
@NP	S100 protein -LRB- red -RRB-	34240
@NP	S100 protein	34240
@NP	red	34254
@NP	Hoechst	34263
@NP	blue nuclear	34276
@NP	the absence of NT-3	34304
@NP	the absence	34304
@NP	NT-3	34319
@NP	virtually no neurite extension from DRG explants	34325
@NP	virtually no neurite extension	34325
@NP	DRG explants	34361
@NP	addition of NT-3 -LRB- 50 ng/ml -RRB- to the culture medium	34405
@NP	addition	34405
@NP	NT-3 -LRB- 50 ng/ml -RRB- to the culture medium	34417
@NP	NT-3 -LRB- 50 ng/ml -RRB-	34417
@NP	NT-3	34417
@NP	50 ng/ml	34423
@NP	the culture medium	34436
@NP	robust , radial fibre outgrowth	34463
@NP	the explant	34499
@NP	the increased dispersal of Schwann cells in the presence of NT-3	34517
@NP	the increased dispersal	34517
@NP	Schwann cells in the presence of NT-3	34544
@NP	Schwann cells	34544
@NP	the presence of NT-3	34561
@NP	the presence	34561
@NP	NT-3	34577
@NP	Scale bars : A , B = 50 µm ; D , E = 100 µm .	34583
@NP	Scale bars	34583
@NP	A , B = 50 µm	34595
@NP	A	34595
@NP	B = 50 µm	34598
@NP	B	34598
@NP	= 50 µm	34600
@NP	50	34602
@NP	D , E = 100 µm	34609
@NP	D	34609
@NP	E = 100 µm	34612
@NP	E	34612
@NP	= 100 µm	34614
@NP	100	34616
@NP	Analysis of transgene expression	34625
@NP	Analysis	34625
@NP	transgene expression	34637
@NP	Primary p75-purified OEG cultures	34658
@NP	first generation E1-deleted AdV vectors	34725
@NP	LacZ or NT-3	34774
@NP	m.o.i. 100 ; Fig. 1A and B	34788
@NP	m.o.i. 100	34788
@NP	Fig. 1A and B	34800
@NP	High levels of transgene expression	34816
@NP	High levels	34816
@NP	transgene expression	34831
@NP	> 95 % of the cells	34872
@NP	> 95 %	34872
@NP	>	34872
@NP	the cells	34880
@NP	3 days	34904
@NP	infection	34917
@NP	Transduced cells	34928
@NP	similar morphology	34955
@NP	OEG cultures	34985
@NP	cytotoxicity	34999
@NP	control cultures	35032
@NP	no expression of either LacZ or NT-3 -LRB- not shown -RRB-	35056
@NP	no expression	35056
@NP	either LacZ or NT-3	35073
@NP	LacZ	35080
@NP	NT-3	35088
@NP	Conditioned medium from OEG cultures	35106
@NP	Conditioned medium	35106
@NP	OEG cultures	35130
@NP	the presence of NT-3	35160
@NP	the presence	35160
@NP	NT-3	35176
@NP	standard ELISA	35187
@NP	4 days	35203
@NP	AdV vector transduction	35216
@NP	AdV-NT-3 vector-transduced cultures	35241
@NP	net NT-3 levels of 40 ± 7.4 ng/10 ^ 5 cells/24	35286
@NP	net NT-3 levels	35286
@NP	40 ± 7.4 ng/10 ^ 5 cells/24	35305
@NP	NT-3 protein	35334
@NP	non-transduced and OEGLacZ cultures	35372
@NP	Biological activity of AdV vector-derived NT-3	35409
@NP	Biological activity	35409
@NP	AdV vector-derived NT-3	35432
@NP	neurite outgrowth	35483
@NP	embryonic DRG explants in the presence of conditioned medium	35506
@NP	embryonic DRG explants	35506
@NP	the presence of conditioned medium	35532
@NP	the presence	35532
@NP	conditioned medium	35548
@NP	OEG cultures	35572
@NP	2 days	35592
@NP	robust neurite outgrowth	35600
@NP	DRG explants	35648
@NP	supernatant	35670
@NP	OEGNT - 3 cultures -LRB- Fig. 1C and D -RRB-	35687
@NP	OEGNT	35687
@NP	3 cultures	35694
@NP	Fig. 1C and D	35706
@NP	Fig. 1C	35706
@NP	D	35718
@NP	Virtually no neuritic growth	35722
@NP	DRG explants	35769
@NP	conditioned medium	35801
@NP	either non-transduced OEG or OEGLacZ cultures	35825
@NP	non-transduced OEG	35832
@NP	OEGLacZ cultures	35854
@NP	Fig. 1E	35872
@NP	In vivo analysis of transgene expression	35882
@NP	In vivo analysis	35882
@NP	transgene expression	35902
@NP	endogenous levels	35947
@NP	there	35966
@NP	robust NT-3 mRNA expression	35976
@NP	the damaged area at 7 days post-implantation -LRB- Fig. 1F -RRB-	36007
@NP	the damaged area	36007
@NP	7 days post-implantation -LRB- Fig. 1F -RRB-	36027
@NP	7 days post-implantation	36027
@NP	Fig. 1F	36053
@NP	Numerous labelled cells of bipolar OEG morphology	36063
@NP	Numerous	36063
@NP	cells of bipolar OEG morphology	36081
@NP	cells	36081
@NP	bipolar OEG morphology	36090
@NP	the transplantation area	36130
@NP	No such staining	36156
@NP	animals that received injections with OEG-LacZ or ` medium only	36188
@NP	animals	36188
@NP	injections	36210
@NP	OEG-LacZ or ` medium	36226
@NP	Ruitenberg et al. , 2003	36279
@NP	Ruitenberg	36279
@NP	et al.	36290
@NP	2003	36298
@NP	p75 labelling	36313
@NP	adjacent immunoreacted spinal cord sections	36330
@NP	regions containing intense NT-3 mRNA expression	36396
@NP	regions	36396
@NP	intense NT-3 mRNA expression	36415
@NP	Behavioural analysis	36445
@NP	field testing	36471
@NP	Behavioural analysis	36485
@NP	OEG-grafted rats during over-ground locomotion -LRB- BBB score -RRB-	36509
@NP	OEG-grafted rats	36509
@NP	over-ground locomotion -LRB- BBB score -RRB-	36533
@NP	over-ground locomotion	36533
@NP	BBB score	36557
@NP	detectable changes	36583
@NP	control	36607
@NP	animals over the analysed period -LRB- 10 weeks -RRB-	36633
@NP	animals	36633
@NP	the analysed period -LRB- 10 weeks -RRB-	36646
@NP	the analysed period	36646
@NP	10 weeks	36667
@NP	Gait	36678
@NP	plantar steps	36734
@NP	there	36752
@NP	only occasional coordination between fore - and hindlimbs	36762
@NP	only occasional coordination between fore	36762
@NP	only occasional coordination	36762
@NP	fore	36799
@NP	hindlimbs	36809
@NP	A steady rating of 12	36820
@NP	A steady rating	36820
@NP	12	36839
@NP	all animals	36857
@NP	week 4 onwards	36874
@NP	Movement analysis	36890
@NP	pellet retrieval success ratings Body rotation after surgery	36912
@NP	pellet retrieval success ratings Body rotation	36912
@NP	surgery	36965
@NP	most experimental animals	36989
@NP	they	37018
@NP	difficulties in raising the right forelimb	37027
@NP	difficulties	37027
@NP	the right forelimb	37051
@NP	The head and shoulders	37071
@NP	The head	37071
@NP	shoulders	37084
@NP	anticlockwise motion	37108
@NP	90 °	37136
@NP	the right forelimb	37151
@NP	the air	37184
@NP	The forepaw	37193
@NP	the food pellet	37228
@NP	the limb	37248
@NP	it	37280
@NP	the inner edge of the shelf	37291
@NP	the inner edge	37291
@NP	the shelf	37309
@NP	Fig. 2A	37337
@NP	Components such as grasp , supination and release	37346
@NP	Components	37346
@NP	grasp , supination and release	37365
@NP	Pre-surgery baseline level of success	37418
@NP	Pre-surgery baseline level	37418
@NP	success	37448
@NP	18 -- 23 pellets eaten in 2 min	37457
@NP	18 -- 23	37457
@NP	pellets	37463
@NP	2 min	37480
@NP	P > 0.05	37520
@NP	P	37520
@NP	> 0.05	37522
@NP	>	37522
@NP	0.05	37524
@NP	the experimental groups	37538
@NP	Movement rating	37563
@NP	2 weeks	37589
@NP	surgery -LRB- week 3 -RRB-	37607
@NP	surgery	37607
@NP	week 3	37616
@NP	pellet retrieval	37630
@NP	all groups -LRB- 0 -- 6 pellets eaten in 2 min ; see Fig. 2B -RRB-	37676
@NP	all groups	37676
@NP	0 -- 6 pellets eaten in 2 min ; see Fig. 2B	37688
@NP	0 -- 6	37688
@NP	pellets	37692
@NP	2 min ; see Fig. 2B	37709
@NP	2 min	37709
@NP	Fig. 2B	37720
@NP	All experimental animals	37730
@NP	12 weeks	37773
@NP	surgery	37788
@NP	success ratings	37812
@NP	all groups -LRB- 9 -- 25 pellets / 2 min -RRB-	37848
@NP	all groups	37848
@NP	9 -- 25 pellets / 2 min	37860
@NP	9 -- 25 pellets /	37860
@NP	9	37860
@NP	25 pellets	37862
@NP	2 min	37874
@NP	Repeated measures ANOVA	37882
@NP	Repeated measures	37882
@NP	ANOVA	37900
@NP	a statistically significant improvement in animals ' success ratings	37913
@NP	a statistically significant improvement	37913
@NP	animals ' success ratings	37956
@NP	animals '	37956
@NP	time -LRB- P < 0.001 -RRB-	37986
@NP	time	37986
@NP	P < 0.001	37992
@NP	P	37992
@NP	< 0.001	37994
@NP	<	37994
@NP	0.001	37996
@NP	the experimental groups -LRB- P = 0.110 -RRB-	38020
@NP	the experimental groups	38020
@NP	P	38045
@NP	0.110	38049
@NP	Pre-surgery movement ratings for all experimental animals	38057
@NP	Pre-surgery movement ratings	38057
@NP	all experimental animals	38090
@NP	0 and 2	38135
@NP	normal forelimb performance	38155
@NP	Movement ratings	38184
@NP	all animals	38231
@NP	surgery	38249
@NP	abnormalities	38269
@NP	forelimb function	38286
@NP	the test period -LRB- 11.3 -- 15.2 ; Fig. 2C -RRB-	38346
@NP	the test period	38346
@NP	11.3	38363
@NP	15.2 ; Fig. 2C	38368
@NP	15.2	38368
@NP	Fig. 2C	38374
@NP	Repeated measures ANOVA	38384
@NP	Repeated measures	38384
@NP	ANOVA	38402
@NP	no statistically significant changes	38415
@NP	postsurgery movement rating over time -LRB- P = 0.503 -RRB-	38455
@NP	postsurgery movement rating	38455
@NP	time -LRB- P = 0.503 -RRB-	38488
@NP	time	38488
@NP	P	38494
@NP	0.503	38498
@NP	differences between the experimental groups -LRB- P = 0.506 -RRB-	38509
@NP	differences	38509
@NP	the experimental groups -LRB- P = 0.506 -RRB-	38529
@NP	the experimental groups	38529
@NP	P	38554
@NP	0.506	38558
@NP	Pellet retrieval	38566
@NP	movement ratings	38590
@NP	Behaviour of all animals , regardless of experimental treatment	38607
@NP	Behaviour	38607
@NP	all animals , regardless of experimental treatment	38620
@NP	all animals	38620
@NP	experimental treatment	38647
@NP	a pattern of improvement in pellet retrieval success rating	38686
@NP	a pattern	38686
@NP	improvement in pellet retrieval success rating	38699
@NP	improvement	38699
@NP	pellet retrieval success rating	38714
@NP	corresponding restoration	38754
@NP	skilled forelimb use	38783
@NP	animal no. 18 ; Fig. 2D , left panel	38820
@NP	animal no.	38820
@NP	18 ; Fig. 2D ,	38831
@NP	18	38831
@NP	Fig. 2D	38835
@NP	panel	38849
@NP	An exception to this pattern	38857
@NP	An exception	38857
@NP	this pattern	38873
@NP	OEG-NT-3-transplated rat 11	38899
@NP	a concurrent loss of both success and movement ratings over the first 7 weeks	38947
@NP	a concurrent loss	38947
@NP	both success and movement ratings over the first 7 weeks	38968
@NP	both success and movement ratings	38968
@NP	the first 7 weeks	39007
@NP	a simultaneous improvement of these parameters	39044
@NP	a simultaneous improvement	39044
@NP	these parameters	39074
@NP	week	39096
@NP	7 to 9 -LRB- Fig. 2D , right panel -RRB-	39101
@NP	7 to 9	39101
@NP	Fig. 2D	39109
@NP	right panel	39118
@NP	week 9	39138
@NP	the movement rating	39155
@NP	pellet retrieval	39210
@NP	Histological analysis Anterograde CST tracing Both dorso-medial CST projections	39249
@NP	Histological analysis Anterograde CST	39249
@NP	Both	39295
@NP	dorso-medial CST projections	39300
@NP	either BDA-G or BDA-R	39348
@NP	BDA-G	39355
@NP	BDA-R	39364
@NP	illustrated -LRB- see diagram , Fig. 3A -RRB-	39373
@NP	illustrated	39373
@NP	diagram , Fig. 3A	39390
@NP	Normal , uninjured Fischer 344 rats -LRB- n = 2 -RRB-	39409
@NP	Normal , uninjured Fischer 344 rats	39409
@NP	n	39445
@NP	2	39449
@NP	the tracing procedure -LRB- Fig. 3B and C -RRB-	39474
@NP	the tracing procedure	39474
@NP	Fig. 3B and C	39497
@NP	Fig. 3B	39497
@NP	C	39509
@NP	The border between the two projections	39513
@NP	The border	39513
@NP	the two projections	39532
@NP	numbers of axons -LRB- < 5 % -RRB-	39590
@NP	numbers	39590
@NP	axons -LRB- < 5 % -RRB-	39601
@NP	axons	39601
@NP	< 5 %	39608
@NP	<	39608
@NP	5 %	39609
@NP	the injected cortical hemisphere	39642
@NP	CST projections in experimental animals	39676
@NP	CST projections	39676
@NP	experimental animals	39695
@NP	processing	39756
@NP	≈ 50 sagittal sections -LRB- 40 µm -RRB-	39768
@NP	≈ 50 sagittal sections	39768
@NP	40 µm	39791
@NP	rat , 8 -- 10 of which contained BDA-G-labelled fibres	39816
@NP	rat	39816
@NP	8 -- 10 of which contained BDA-G-labelled fibres	39821
@NP	8 -- 10	39821
@NP	BDA-G-labelled fibres	39845
@NP	all operated rats	39871
@NP	all	39871
@NP	rats	39884
@NP	CST axons	39890
@NP	enlarged , dystrophic ends and sprouts	39914
@NP	the lesion site	39969
@NP	the BDA-Glabelled CST	39999
@NP	wider	40031
@NP	more proximal undamaged parts	40050
@NP	Virtually no BDA-G-labelled fibres	40081
@NP	the lesion area itself	40129
@NP	the lesion area	40129
@NP	distal spinal cord in vehicleinjected controls , or OEG -	40158
@NP	distal spinal cord	40158
@NP	vehicleinjected controls , or OEG -	40180
@NP	vehicleinjected controls	40180
@NP	OEG	40209
@NP	OEG-LacZ-implanted rats -LRB- Fig. 3D -RRB-	40218
@NP	OEG-LacZ-implanted rats	40218
@NP	Fig. 3D	40243
@NP	Immunohistochemistry for GFAP	40253
@NP	Immunohistochemistry	40253
@NP	GFAP	40278
@NP	the presence of hypertrophic astrocytes	40290
@NP	the presence	40290
@NP	hypertrophic astrocytes	40306
@NP	a 200 -- 300 µm radius of the damaged area -LRB- Fig. 3E -RRB-	40337
@NP	a 200	40337
@NP	300 µm radius of the damaged area -LRB- Fig. 3E -RRB-	40343
@NP	300 µm radius	40343
@NP	the damaged area -LRB- Fig. 3E -RRB-	40360
@NP	the damaged area	40360
@NP	Fig. 3E	40378
@NP	lesioned BDA-G-labelled CST axons abutting the proximal border of the glial scar	40393
@NP	lesioned BDA-G-labelled CST axons	40393
@NP	the proximal border of the glial scar	40436
@NP	the proximal border	40436
@NP	the glial scar	40459
@NP	all transplanted animals	40478
@NP	the phenotypic appearance and purity	40504
@NP	primary OEG preparations	40544
@NP	the olfactory bulbs of adult Fischer 344 rats	40585
@NP	the olfactory bulbs	40585
@NP	adult Fischer 344 rats	40608
@NP	transplantation	40655
@NP	OEG	40681
@NP	S100 -LRB- not shown -RRB- , GFAP and p75 -LRB- Fig. 4A -RRB-	40709
@NP	S100 -LRB- not shown -RRB-	40709
@NP	S100	40709
@NP	GFAP and p75 -LRB- Fig. 4A -RRB-	40727
@NP	GFAP and p75	40727
@NP	Fig. 4A	40741
@NP	The purity of all cultures used for transplantation purposes	40751
@NP	The purity	40751
@NP	all cultures used for transplantation purposes	40765
@NP	all cultures	40765
@NP	transplantation purposes	40787
@NP	between 95 and 98 %	40816
@NP	the ratio of p75-stained cells	40855
@NP	the ratio	40855
@NP	p75-stained cells	40868
@NP	the total cell number	40889
@NP	12 weeks	40918
@NP	numerous p75 - immunoreactive cells	40928
@NP	numerous p75	40928
@NP	immunoreactive cells	40942
@NP	the damaged area of all OEG-transplanted animals -LRB- Fig. 4B -RRB-	40980
@NP	the damaged area	40980
@NP	all OEG-transplanted animals -LRB- Fig. 4B -RRB-	41000
@NP	all OEG-transplanted animals	41000
@NP	Fig. 4B	41030
@NP	Many fewer cells	41040
@NP	most	41058
@NP	host Schwann cells	41072
@NP	the injured cord -LRB- Ruitenberg et al. , 2003 -RRB-	41108
@NP	the injured cord	41108
@NP	Ruitenberg	41126
@NP	et al. , 2003	41137
@NP	et al.	41137
@NP	2003	41145
@NP	vehicle-injected controls	41166
@NP	four out of the five animals analysed receiving OEG-NT-3 implants	41205
@NP	four	41205
@NP	the five animals	41217
@NP	OEG-NT-3 implants	41253
@NP	BDA-G-labelled fibres	41278
@NP	the proximal mass	41315
@NP	lesioned CST axons	41336
@NP	the lesion site	41363
@NP	more distal parts of the spinal cord as far as	41388
@NP	more distal parts	41388
@NP	the spinal cord as far as	41409
@NP	the spinal cord	41409
@NP	at least 1 cm -LRB- Fig. 4C -RRB-	41435
@NP	at least 1 cm	41435
@NP	Fig. 4C	41450
@NP	These distal CST axons	41460
@NP	distribution	41501
@NP	a beaded appearance and uneven trajectory -LRB- Fig. 4D -RRB-	41519
@NP	a beaded appearance	41519
@NP	uneven trajectory -LRB- Fig. 4D -RRB-	41543
@NP	uneven trajectory	41543
@NP	Fig. 4D	41562
@NP	regeneratingCSTfibres -LRB- Steward et al. , 2003 -RRB-	41617
@NP	regeneratingCSTfibres	41617
@NP	Steward	41640
@NP	et al. , 2003	41648
@NP	et al.	41648
@NP	2003	41656
@NP	the transverse sections	41666
@NP	no BDA-G fibres	41691
@NP	1 cm distal to the lesion site in any of the vehicle-injected	41717
@NP	1 cm	41717
@NP	the lesion site in any of the vehicle-injected	41732
@NP	the lesion site	41732
@NP	any of the vehicle-injected	41751
@NP	any	41751
@NP	the vehicle-injected	41758
@NP	OEG	41780
@NP	OEG-LacZ-implanted rats -LRB- Fig. 4E -RRB-	41788
@NP	OEG-LacZ-implanted rats	41788
@NP	Fig. 4E	41813
@NP	Distal BDA-G-labelled CST axons	41823
@NP	this level in four of the five OEG-NT-3	41878
@NP	this level	41878
@NP	four of the five OEG-NT-3	41892
@NP	four	41892
@NP	the five OEG-NT-3	41900
@NP	transplanted animals -LRB- Fig. 4F -RRB-	41918
@NP	transplanted animals	41918
@NP	Fig. 4F	41940
@NP	average	41953
@NP	≈ 9 % of proximally labelled fibres	41962
@NP	≈ 9 %	41962
@NP	proximally labelled fibres	41969
@NP	at least 1 cm	42006
@NP	the lesion site -LRB- see later -RRB- , which was the maximum distance measured	42030
@NP	the lesion site -LRB- see later -RRB-	42030
@NP	the lesion site	42030
@NP	the maximum distance measured	42069
@NP	the maximum distance	42069
@NP	These labelled axons	42100
@NP	These	42100
@NP	axons	42115
@NP	a localized area of white matter	42170
@NP	a localized area	42170
@NP	white matter	42190
@NP	the latter organization being	42204
@NP	an incomplete CST lesion	42253
@NP	Quantification of dorsal	42279
@NP	Quantification	42279
@NP	dorsal	42297
@NP	CST axons	42304
@NP	Labelled CST fibres in sagittal sections	42314
@NP	Labelled CST fibres	42314
@NP	sagittal sections	42337
@NP	signal fluorescence	42384
@NP	four distances in a rostral	42407
@NP	four distances	42407
@NP	a rostral	42425
@NP	caudal direction across the lesion site	42438
@NP	caudal direction	42438
@NP	the lesion site	42462
@NP	Fig. 5A and B	42479
@NP	Fig. 5A	42479
@NP	B	42491
@NP	These values	42495
@NP	each experimental group , i.e.	42531
@NP	each experimental group	42531
@NP	i.e.	42556
@NP	vehicle-injected , OEG - , OEG-LacZ	42561
@NP	vehicle-injected , OEG -	42561
@NP	vehicle-injected	42561
@NP	OEG	42579
@NP	OEG-LacZ	42585
@NP	OEG-NT-3 - transplanted rats -LRB- Fig. 5C -RRB-	42599
@NP	OEG-NT-3	42599
@NP	transplanted rats -LRB- Fig. 5C -RRB-	42609
@NP	transplanted rats	42609
@NP	Fig. 5C	42628
@NP	The fluorescence intensity of CST fibres	42638
@NP	The fluorescence intensity	42638
@NP	CST fibres	42668
@NP	the lesion area -LRB- -1.0 mm -RRB-	42705
@NP	the lesion area	42705
@NP	-1.0 mm	42722
@NP	the centre -LRB- 0 mm -RRB-	42754
@NP	the centre	42754
@NP	0 mm	42766
@NP	more distal parts of the lesion -LRB- + 0.5 and + 1.0 mm -RRB-	42776
@NP	more distal parts	42776
@NP	the lesion -LRB- + 0.5 and + 1.0 mm -RRB-	42797
@NP	the lesion	42797
@NP	+ 0.5 and + 1.0	42809
@NP	0.5 and	42811
@NP	1.0	42821
@NP	mm	42825
@NP	There	42830
@NP	a trend	42840
@NP	increased numbers	42856
@NP	distal CST axons	42877
@NP	the OEG-NT-3-implanted animal group	42897
@NP	consistently higher signal fluorescence	42942
@NP	the lesion centre	42985
@NP	more caudal parts	43007
@NP	the spinal cord than all other experimental groups -LRB- Fig. 5C -RRB-	43028
@NP	the spinal cord	43028
@NP	all other experimental groups -LRB- Fig. 5C -RRB-	43049
@NP	all other experimental groups	43049
@NP	Fig. 5C	43080
@NP	Simple contrast tests	43090
@NP	statistical significance	43124
@NP	increased fluorescence measures in the OEGNT - 3 group	43152
@NP	increased fluorescence measures	43152
@NP	the OEGNT - 3 group	43187
@NP	the OEGNT	43187
@NP	3 group	43198
@NP	both + 0.5 mm -LRB- P = 0.085 -RRB-	43226
@NP	both	43226
@NP	0.5 mm	43233
@NP	P	43241
@NP	0.085	43245
@NP	+	43256
@NP	1.0 mm -LRB- P = 0.066 -RRB-	43258
@NP	1.0 mm	43258
@NP	P	43266
@NP	0.066	43270
@NP	its control , the OEG-LacZ group	43296
@NP	its control	43296
@NP	the OEG-LacZ group	43309
@NP	transverse sections	43332
@NP	the density	43353
@NP	CST fibres	43368
@NP	both BDA-G -LRB- lesioned -RRB- and BDA-R -LRB- uninjured -RRB-	43386
@NP	both BDA-G	43386
@NP	BDA-R	43412
@NP	projections	43439
@NP	1 cm distal to the injury	43454
@NP	1 cm	43454
@NP	the injury	43469
@NP	a percentage of total label -LRB- measured 1 cm proximal to the injury -RRB-	43497
@NP	a percentage	43497
@NP	total label	43513
@NP	1 cm	43535
@NP	the injury	43552
@NP	vehicle-injected control animals	43568
@NP	signal fluorescence 1 cm distal to the injury site	43602
@NP	signal fluorescence	43602
@NP	1 cm	43622
@NP	the injury site	43637
@NP	only 0.66 6 0.2 % -LRB- mean ± SEM ; n = 5 -RRB- of the proximal signal	43668
@NP	only 0.66 6 0.2 %	43668
@NP	only 0.66	43668
@NP	mean ± SEM ; n = 5	43686
@NP	mean ± SEM	43686
@NP	n = 5	43698
@NP	n	43698
@NP	5	43702
@NP	the proximal signal	43708
@NP	Similar values	43729
@NP	the OEG -	43759
@NP	the OEG	43759
@NP	1.5 ±	43769
@NP	0.7 % ; n = 5	43775
@NP	0.7 %	43775
@NP	n = 5	43781
@NP	n	43781
@NP	5	43785
@NP	OEG-LacZ	43792
@NP	1.1 ±	43803
@NP	0.2 % ; n = 5	43809
@NP	0.2 %	43809
@NP	n = 5	43815
@NP	n	43815
@NP	5	43819
@NP	groups	43835
@NP	OEG-NT-3-transplanted animals	43858
@NP	much higher values of ≈ 9 % of the proximal label	43889
@NP	much higher values	43889
@NP	≈ 9 % of the proximal label	43911
@NP	≈ 9 %	43911
@NP	the proximal label	43918
@NP	1 cm	43947
@NP	the injury site	43958
@NP	9.1 ±	43975
@NP	1.43 % ; n = 5 ; Fig. 5D	43981
@NP	1.43 %	43981
@NP	n = 5	43988
@NP	n	43988
@NP	5	43992
@NP	Fig. 5D	43995
@NP	analysis	44024
@NP	a significant overall treatment effect	44042
@NP	the experimental groups -LSB- F -LRB- 3,20 -RRB- = 15.45	44089
@NP	the experimental groups -LSB- F -LRB- 3,20 -RRB-	44089
@NP	the experimental groups -LSB- F	44089
@NP	3,20	44116
@NP	15.45	44124
@NP	P = 0.0001	44131
@NP	P	44131
@NP	0.0001	44135
@NP	Further analysis	44144
@NP	no statistical differences	44168
@NP	groups	44203
@NP	vehicle injections , OEG or OEG-LacZ transplants	44224
@NP	P > 0.57	44273
@NP	P	44273
@NP	> 0.57	44275
@NP	>	44275
@NP	0.57	44277
@NP	the distal CST label in OEG-NT-3-transplanted animals	44288
@NP	the distal CST label	44288
@NP	OEG-NT-3-transplanted animals	44312
@NP	other groups -LRB- P < 0.0005 -RRB-	44382
@NP	other groups	44382
@NP	P < 0.0005	44396
@NP	P	44396
@NP	< 0.0005	44398
@NP	<	44398
@NP	0.0005	44400
@NP	There	44409
@NP	no evidence	44419
@NP	progressive changes in BDA-R-labelled fibre densities or compensatory growth	44434
@NP	progressive changes	44434
@NP	BDA-R-labelled fibre densities or compensatory growth	44457
@NP	BDA-R-labelled fibre densities	44457
@NP	compensatory growth	44491
@NP	the BDA-G projection	44516
@NP	termination areas	44541
@NP	the injury site	44569
@NP	OEG transplants	44586
@NP	tissue sparing Spinal tissue sparing	44610
@NP	tissue	44610
@NP	Spinal tissue sparing	44625
@NP	the damaged area	44667
@NP	cysts , degenerate tissue and transplanted OEG	44695
@NP	cysts	44695
@NP	degenerate tissue and transplanted OEG	44702
@NP	degenerate tissue	44702
@NP	transplanted OEG	44724
@NP	a 2.5 mm long spinal cord segment -LRB- Fig. 6A -RRB-	44749
@NP	a 2.5 mm long spinal cord segment	44749
@NP	2.5 mm	44751
@NP	Fig. 6A	44784
@NP	the vehicle-injected group	44797
@NP	75.2 ± 4.8 % -LRB- mean ± SEM , n = 5 -RRB- of the spinal cord segment examined	44825
@NP	75.2 ± 4.8 % -LRB- mean ± SEM , n = 5 -RRB-	44825
@NP	75.2 ± 4.8 %	44825
@NP	75.2 ±	44825
@NP	4.8 %	44832
@NP	mean ± SEM , n = 5	44838
@NP	mean ± SEM	44838
@NP	n = 5	44850
@NP	n	44850
@NP	5	44854
@NP	the spinal cord segment examined	44860
@NP	the spinal cord segment	44860
@NP	contrast	44908
@NP	significantly more -LRB- P < 0.006 -RRB- spinal tissue	44918
@NP	P < 0.006	44938
@NP	P	44938
@NP	< 0.006	44940
@NP	<	44940
@NP	0.006	44942
@NP	OEG -	44977
@NP	OEG	44977
@NP	87.7 ±	44983
@NP	1.0 % ; n = 5	44990
@NP	1.0 %	44990
@NP	n = 5	44996
@NP	n	44996
@NP	5	45000
@NP	OEG-LacZ	45004
@NP	87.5 ±	45015
@NP	0.9 % ; n = 5	45022
@NP	0.9 %	45022
@NP	n = 5	45028
@NP	n	45028
@NP	5	45032
@NP	OEG-NT-3	45039
@NP	87.7 ±	45050
@NP	0.8 % ; n = 5	45057
@NP	0.8 %	45057
@NP	n = 5	45063
@NP	n	45063
@NP	5	45067
@NP	groups	45080
@NP	Mean cyst area and number	45088
@NP	Mean cyst area	45088
@NP	number	45107
@NP	experimental groups	45135
@NP	P > 0.05 ; Fig. 6B	45156
@NP	P	45156
@NP	> 0.05 ; Fig. 6B	45158
@NP	> 0.05	45158
@NP	>	45158
@NP	0.05	45160
@NP	Fig. 6B	45166
@NP	The amount of degenerate tissue	45176
@NP	The amount	45176
@NP	degenerate tissue	45190
@NP	all transplanted animals -LRB- P < 0.004 ; Fig. 6C -RRB-	45239
@NP	all transplanted animals	45239
@NP	P < 0.004 ; Fig. 6C	45265
@NP	P	45265
@NP	< 0.004 ; Fig. 6C	45267
@NP	< 0.004	45267
@NP	<	45267
@NP	0.004	45269
@NP	Fig. 6C	45276
@NP	all OEG-transplanted animals	45299
@NP	greater p75 immunoreactivity	45332
@NP	the grafted area	45364
@NP	medium-injected control rats -LRB- P < 0.0001 ; Fig. 6D -RRB-	45386
@NP	medium-injected control rats	45386
@NP	P < 0.0001 ; Fig. 6D	45416
@NP	P	45416
@NP	< 0.0001 ; Fig. 6D	45418
@NP	< 0.0001	45418
@NP	<	45418
@NP	0.0001	45420
@NP	Fig. 6D	45428
@NP	there	45444
@NP	no significant difference between OEG	45454
@NP	no significant difference	45454
@NP	OEG	45488
@NP	OEG-LacZ groups -LRB- P = 0.78 -RRB- , the p75	45496
@NP	OEG-LacZ groups	45496
@NP	P	45513
@NP	0.78	45517
@NP	the p75	45524
@NP	positive area in the OEG-NT-3 group	45533
@NP	positive area	45533
@NP	the OEG-NT-3 group	45550
@NP	all other OEG-transplanted groups	45599
@NP	P < 0.004	45634
@NP	P	45634
@NP	< 0.004	45636
@NP	<	45636
@NP	0.004	45638
@NP	This increase	45646
@NP	improved survival	45675
@NP	proliferation of engineered donor cells -LRB- Bianco et al. , 2004 -RRB-	45700
@NP	proliferation	45700
@NP	engineered donor cells -LRB- Bianco et al. , 2004 -RRB-	45717
@NP	engineered donor cells	45717
@NP	Bianco	45741
@NP	et al. , 2004	45748
@NP	et al.	45748
@NP	2004	45756
@NP	host	45787
@NP	Schwann cell invasion in this group -LRB- Ramer et al. , 2004 -RRB-	45792
@NP	Schwann cell invasion	45792
@NP	this group -LRB- Ramer et al. , 2004 -RRB-	45817
@NP	this group	45817
@NP	Ramer	45829
@NP	et al. , 2004	45835
@NP	et al.	45835
@NP	2004	45843
@NP	an additional series of in vitro experiments	45853
@NP	an additional series	45853
@NP	experiments	45886
@NP	we	45899
@NP	the mitogenic effects	45910
@NP	NT-3 on adult OEG cultures via BrdU incorporation	45953
@NP	NT-3	45953
@NP	adult OEG cultures via BrdU incorporation	45961
@NP	adult OEG cultures	45961
@NP	BrdU incorporation	45984
@NP	Cells	46004
@NP	serum-free -LRB- CD -RRB- or mitogen-containing -LRB- DF-10S -RRB- medium.We	46031
@NP	serum-free -LRB- CD -RRB-	46031
@NP	serum-free	46031
@NP	mitogen-containing -LRB- DF-10S -RRB- medium.We	46048
@NP	DF-10S	46068
@NP	no evidence	46091
@NP	transduction of cells with AdV-NT-3	46108
@NP	transduction	46108
@NP	cells with AdV-NT-3	46124
@NP	cells	46124
@NP	AdV-NT-3	46135
@NP	increased proliferation	46156
@NP	purified adult OEG that were obtained from the olfactory bulb nerve layer	46183
@NP	purified adult OEG	46183
@NP	the olfactory bulb nerve layer	46226
@NP	Additional experiments , adding recombinant NT-3 to OEG cultures ,	46258
@NP	Additional experiments	46258
@NP	recombinant NT-3	46289
@NP	OEG cultures	46309
@NP	no mitogenic effects of this neurotrophin	46335
@NP	no mitogenic effects	46335
@NP	this neurotrophin	46359
@NP	any concentration -LRB- Fig. 7A -- C -RRB-	46380
@NP	any concentration	46380
@NP	Fig. 7A -- C	46399
@NP	Fig. 7A	46399
@NP	C	46407
@NP	Further analysis of total cell numbers after plating	46411
@NP	Further analysis	46411
@NP	total cell numbers after plating	46431
@NP	total cell numbers	46431
@NP	plating	46456
@NP	any effects of NT-3	46481
@NP	any effects	46481
@NP	NT-3	46496
@NP	OEG viability	46504
@NP	the 2 day time period	46533
@NP	DRGs	46601
@NP	the presence of NT-3	46625
@NP	the presence	46625
@NP	NT-3	46641
@NP	biological activity of this recombinant neurotrophin	46658
@NP	biological activity	46658
@NP	this recombinant neurotrophin	46681
@NP	addition to robust neurite outgrowth	46727
@NP	addition	46727
@NP	robust neurite outgrowth	46739
@NP	there	46765
@NP	Schwann cell dispersal	46790
@NP	the explants	46818
@NP	Fig. 7C and D	46832
@NP	Fig. 7C	46832
@NP	D	46844
@NP	The latter observation	46848
@NP	an effect	46890
@NP	NT-3 on Schwann cell migration and chemokinesis -LRB- Maniwa et al. , 2003 -RRB-	46903
@NP	NT-3 on Schwann cell migration	46903
@NP	NT-3	46903
@NP	Schwann cell migration	46911
@NP	chemokinesis -LRB- Maniwa et al. , 2003 -RRB-	46938
@NP	chemokinesis	46938
@NP	Maniwa	46952
@NP	et al. , 2003	46959
@NP	et al.	46959
@NP	2003	46967
@NP	Discussion We report the effects of genetically	46975
@NP	Discussion	46975
@NP	We	46986
@NP	the effects	46996
@NP	OEG transplants	47032
@NP	spinal cord tissue sparing and CST sprouting/regeneration	47051
@NP	cervical injury in rats	47115
@NP	cervical injury	47115
@NP	rats	47134
@NP	spinal cord tissue	47159
@NP	all OEG-transplanted animals	47192
@NP	vehicle-injected controls	47235
@NP	Qualitative and quantitative histological analysis of BDA-G-labelled CST axons	47262
@NP	Qualitative and quantitative histological analysis	47262
@NP	BDA-G-labelled CST axons	47316
@NP	OEG implants	47353
@NP	NT-3	47388
@NP	longdistance maintenance/regrowth	47401
@NP	these axons for up to at least 1 cm distal to the injury site	47438
@NP	these axons	47438
@NP	up to at least 1 cm distal to the injury site	47454
@NP	up to at least 1 cm	47454
@NP	at least 1	47460
@NP	the injury site	47484
@NP	Behavioural analysis	47501
@NP	some post-lesion recovery	47531
@NP	there	47561
@NP	no significant differences between experimental groups	47572
@NP	no significant differences	47572
@NP	experimental groups	47607
@NP	no changes	47631
@NP	the pattern and distribution	47655
@NP	uninjured BDA-R-labelled CST axons distal from the lesion site	47687
@NP	uninjured BDA-R-labelled CST axons	47687
@NP	the lesion site	47734
@NP	our results	47751
@NP	compensatory involvement of intraspinal circuitry	47772
@NP	compensatory involvement	47772
@NP	intraspinal circuitry	47800
@NP	supraspinal pathways	47846
@NP	post-lesion recovery	47870
@NP	OEG-implanted rats	47892
@NP	spinal tissue -LRB- 10 -- 15 % -RRB- at 12 weeks	47941
@NP	spinal tissue -LRB- 10 -- 15 % -RRB-	47941
@NP	spinal tissue	47941
@NP	10 -- 15 %	47956
@NP	10	47956
@NP	15 %	47959
@NP	12 weeks	47967
@NP	injury	47982
@NP	vehicle-injected controls	48003
@NP	This	48030
@NP	the preservation of white matter tracts	48044
@NP	the preservation	48044
@NP	white matter tracts	48064
@NP	intraspinal neurons	48088
@NP	the area	48111
@NP	the primary injury site	48133
@NP	functional adaptation	48184
@NP	the injury	48212
@NP	These findings	48224
@NP	previous reports	48259
@NP	OEG	48289
@NP	spinal cord tissue sparing	48318
@NP	Takami	48346
@NP	et al. , 2002	48353
@NP	et al.	48353
@NP	2002	48361
@NP	Plant et al. , 2003	48367
@NP	Plant	48367
@NP	et al. , 2003	48373
@NP	et al.	48373
@NP	2003	48381
@NP	Ruitenberg et al. , 2003	48387
@NP	Ruitenberg	48387
@NP	et al. , 2003	48398
@NP	et al.	48398
@NP	2003	48406
@NP	Verdu et al. , 2003	48412
@NP	Verdu	48412
@NP	et al. , 2003	48418
@NP	et al.	48418
@NP	2003	48426
@NP	Ramer et al. , 2004	48432
@NP	Ramer	48432
@NP	et al. , 2004	48438
@NP	et al.	48438
@NP	2004	48446
@NP	transplanted animals	48456
@NP	many of the cells present at the site of engraftment	48478
@NP	many	48478
@NP	the cells present at the site of engraftment	48486
@NP	the cells	48486
@NP	the site of engraftment	48507
@NP	the site	48507
@NP	engraftment	48519
@NP	p75	48536
@NP	This population	48550
@NP	the lesion	48574
@NP	the rostral	48590
@NP	caudal extents of intact spinal cord	48605
@NP	caudal extents	48605
@NP	intact spinal cord	48623
@NP	a cellular substrate	48653
@NP	growing axons towards the opposing end of the spinal cord	48678
@NP	growing axons	48678
@NP	the opposing end of the spinal cord	48700
@NP	the opposing end	48700
@NP	the spinal cord	48720
@NP	both vehicle-injected and OEG-implanted animal groups	49214
@NP	the majority of lesioned CST axons	49269
@NP	the majority	49269
@NP	lesioned CST axons	49285
@NP	enlarged bulbous ends	49311
@NP	the proximal edge of the lesion	49339
@NP	the proximal edge	49339
@NP	the lesion	49360
@NP	rats	49375
@NP	vehicle injections or control implants	49394
@NP	OEG and OEG-LacZ groups	49434
@NP	OEG	49434
@NP	OEG-LacZ groups	49442
@NP	CST axons	49460
@NP	the injury site	49494
@NP	agreement with Takami et al. -LRB- 2002 -RRB- but in contrast	49523
@NP	agreement	49523
@NP	Takami et al. -LRB- 2002 -RRB-	49538
@NP	Takami et al.	49538
@NP	Takami	49538
@NP	et al.	49545
@NP	2002	49553
@NP	contrast	49566
@NP	data	49578
@NP	other groups	49595
@NP	Li	49609
@NP	et al. , 1998	49612
@NP	et al.	49612
@NP	1998	49620
@NP	Ramon-Cueto et al. , 2000	49626
@NP	Ramon-Cueto	49626
@NP	et al. , 2000	49638
@NP	et al.	49638
@NP	2000	49646
@NP	Nash et al. , 2002	49652
@NP	Nash	49652
@NP	et al. , 2002	49657
@NP	et al.	49657
@NP	2002	49665
@NP	Keyvan-Fouladi et al. , 2003	49671
@NP	Keyvan-Fouladi	49671
@NP	et al. , 2003	49686
@NP	et al.	49686
@NP	2003	49694
@NP	It	49701
@NP	these discrepancies	49730
@NP	true differences in outcomes	49760
@NP	true differences	49760
@NP	outcomes	49780
@NP	they	49800
@NP	experimental differences in lesion procedures , OEG preparation protocols	49825
@NP	experimental differences	49825
@NP	lesion procedures , OEG preparation protocols	49853
@NP	lesion procedures	49853
@NP	OEG preparation protocols	49872
@NP	purity	49916
@NP	Only in OEG-NT-3 transplanted rats	49924
@NP	Only	49924
@NP	OEG-NT-3 transplanted rats	49932
@NP	there	49963
@NP	evidence of CST	49969
@NP	evidence	49969
@NP	CST	49981
@NP	0.5 and 1 mm distal to the lesion epicentre	49995
@NP	0.5 and 1 mm	49995
@NP	the lesion epicentre	50018
@NP	others	50040
@NP	similar effects of NT-3	50062
@NP	similar effects	50062
@NP	NT-3	50081
@NP	CST axons	50089
@NP	Schnell	50100
@NP	et al. , 1994 ; Senut et al. , 1995 ; Grill et al. , 1997 ; Blits et al. , 2000	50108
@NP	et al. , 1994	50108
@NP	et al.	50108
@NP	1994	50116
@NP	Senut et al. , 1995	50122
@NP	Senut	50122
@NP	et al. , 1995	50128
@NP	et al.	50128
@NP	1995	50136
@NP	Grill et al. , 1997	50142
@NP	Grill	50142
@NP	et al. , 1997	50148
@NP	et al.	50148
@NP	1997	50156
@NP	Blits et al. , 2000	50162
@NP	Blits	50162
@NP	et al. , 2000	50168
@NP	et al.	50168
@NP	2000	50176
@NP	Significantly more BDA-G-labelled CST fibres	50183
@NP	1 cm distal to the lesion in the OEG-NT-3 group	50248
@NP	1 cm	50248
@NP	the lesion in the OEG-NT-3 group	50263
@NP	the lesion	50263
@NP	the OEG-NT-3 group	50277
@NP	These axons	50297
@NP	a beaded appearance -LRB- Li et al. , 1997 -RRB-	50313
@NP	a beaded appearance	50313
@NP	Li	50334
@NP	et al. , 1997	50337
@NP	et al.	50337
@NP	1997	50345
@NP	the damaged area	50365
@NP	the more ventral portions of the lesion and implantation site	50390
@NP	the more ventral portions	50390
@NP	the lesion and implantation site	50419
@NP	Further	50453
@NP	the majority of BDA-G-labelled CST axons	50471
@NP	the majority	50471
@NP	BDA-G-labelled CST axons	50487
@NP	a more scattered , defasciculated pattern	50529
@NP	an uneven trajectory along the rostro-caudal axis of the denervated spinal cord	50575
@NP	an uneven trajectory	50575
@NP	the rostro-caudal axis of the denervated spinal cord	50602
@NP	the rostro-caudal axis	50602
@NP	the denervated spinal cord	50628
@NP	the	50628
@NP	spinal cord	50643
@NP	Such features	50656
@NP	axonal regrowth	50697
@NP	normal CST organization -LRB- Steward et al. , 2003 -RRB-	50718
@NP	normal CST organization	50718
@NP	Steward	50743
@NP	et al. , 2003	50751
@NP	et al.	50751
@NP	2003	50759
@NP	morphological criteria	50775
@NP	true axonal regeneration	50828
@NP	partial spinal cord transection models	50884
@NP	an important area of debate	50931
@NP	an important area	50931
@NP	debate	50952
@NP	our study	50963
@NP	there	50974
@NP	a comparable amount of preserved spinal tissue	50984
@NP	a comparable amount	50984
@NP	preserved spinal tissue	51007
@NP	all OEG transplant paradigms	51034
@NP	the increased number of distal CST axons in the OEG-NT-3 group	51080
@NP	the increased number	51080
@NP	distal CST axons	51104
@NP	the OEG-NT-3 group	51124
@NP	a difference in overall tissue sparing	51158
@NP	a difference	51158
@NP	overall tissue sparing	51174
@NP	Regeneration of at least some CST fibres	51198
@NP	Regeneration	51198
@NP	at least some CST fibres	51214
@NP	it	51267
@NP	NT-3 released from	51292
@NP	NT-3	51292
@NP	OEGhada	51322
@NP	selective andspecific effectonprotectingcompromised CST axons	51330
@NP	subsequent secondary degeneration	51397
@NP	All experimental animals	51432
@NP	skilled forelimb reaching	51473
@NP	skilled forelimb	51473
@NP	They	51500
@NP	severe impairment	51512
@NP	injury followed by partial recovery	51548
@NP	injury	51548
@NP	partial recovery	51567
@NP	Success ratings in transplanted animals	51585
@NP	Success ratings	51585
@NP	transplanted animals	51604
@NP	controls	51659
@NP	the period	51673
@NP	analysis	51687
@NP	the results of Nash	51718
@NP	the results	51718
@NP	Nash	51733
@NP	et al.	51738
@NP	2002	51746
@NP	methylprednisolone administration	51766
@NP	OEG transplantation	51805
@NP	Our results	51826
@NP	the original findings	51856
@NP	Schrimsher and Reier -LRB- 1993 -RRB-	51881
@NP	Schrimsher and Reier	51881
@NP	1993	51903
@NP	a recovery	51924
@NP	the pellet retrieval task performance over time	51938
@NP	the pellet retrieval task performance	51938
@NP	time	51981
@NP	a C4 cervical lesion	51992
@NP	Movement ratings	52014
@NP	the testing period	52065
@NP	the experimental groups	52111
@NP	This	52136
@NP	increasing success in the forelimb reaching task over time	52151
@NP	increasing success	52151
@NP	the forelimb reaching task over time	52173
@NP	the forelimb	52173
@NP	task over time	52195
@NP	task	52195
@NP	time	52205
@NP	no parallel improvement in animals ' movements	52215
@NP	no parallel improvement	52215
@NP	animals ' movements	52242
@NP	animals '	52242
@NP	the food pellets	52274
@NP	our findings	52299
@NP	the improvements in pellet retrieval	52325
@NP	the improvements	52325
@NP	pellet retrieval	52345
@NP	spinal or supraspinal compensatory mechanisms	52373
@NP	spinal	52373
@NP	supraspinal compensatory mechanisms	52383
@NP	adaptation	52432
@NP	recovery of skilled movements due to anatomical CST regeneration	52456
@NP	recovery	52456
@NP	skilled movements due to anatomical CST regeneration	52468
@NP	skilled movements	52468
@NP	anatomical CST regeneration	52493
@NP	Closer inspection of movement ratings -LRB- Whishaw et al. , 1993 -RRB-	52522
@NP	Closer inspection of movement ratings	52522
@NP	Closer inspection	52522
@NP	movement ratings	52543
@NP	Whishaw	52561
@NP	et al. , 1993	52569
@NP	et al.	52569
@NP	1993	52577
@NP	specific task components	52597
@NP	unilateral CST lesions	52639
@NP	These	52663
@NP	supination	52678
@NP	and release of the food pellet	52699
@NP	release of the food pellet	52703
@NP	release	52703
@NP	the food pellet	52714
@NP	Impairments of distal forelimb muscle	52731
@NP	Impairments	52731
@NP	distal forelimb muscle	52746
@NP	similar cervical lesions	52804
@NP	the dorsal columns	52832
@NP	the CST	52864
@NP	Schrimsher and Reier	52873
@NP	1993 ; Whishaw et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52895
@NP	1993	52895
@NP	Whishaw et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52901
@NP	Whishaw	52901
@NP	et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52909
@NP	et al. , 1993	52909
@NP	et al.	52909
@NP	1993	52917
@NP	McKenna and Whishaw , 1999	52923
@NP	McKenna and Whishaw	52923
@NP	1999	52944
@NP	Raineteau et al.	52950
@NP	Raineteau	52950
@NP	et al.	52960
@NP	2001	52968
@NP	It	52975
@NP	future studies involving behavioural analysis	53005
@NP	future studies	53005
@NP	behavioural analysis	53030
@NP	the exact movements	53067
@NP	damage	53110
@NP	specific spinal motor pathways	53120
@NP	the present study	53155
@NP	a task that may have been more sensitive to a CST lesion in rats	53174
@NP	a task	53174
@NP	a CST lesion	53218
@NP	rats	53234
@NP	one requiring supination , grasping and release of the forepaw -LRB- e.g.	53248
@NP	one requiring supination , grasping	53248
@NP	one	53248
@NP	supination	53262
@NP	release of the forepaw -LRB- e.g.	53287
@NP	release	53287
@NP	the forepaw -LRB- e.g.	53298
@NP	the forepaw	53298
@NP	e.g.	53311
@NP	Galea and Darian-Smith , 1997 ; Ballermann et al. , 2001 -RRB- .	53316
@NP	Galea and Darian-Smith	53316
@NP	1997 ; Ballermann et al. , 2001 -RRB-	53340
@NP	1997	53340
@NP	Ballermann et al. , 2001 -RRB-	53346
@NP	Ballermann	53346
@NP	et al.	53357
@NP	2001	53365
@NP	Several mechanisms , other than axonal regeneration ,	53372
@NP	Several mechanisms	53372
@NP	other than axonal regeneration	53392
@NP	other	53392
@NP	axonal regeneration	53403
@NP	functional recovery	53461
@NP	spinal cord injury -LRB- e.g.	53487
@NP	spinal cord injury	53487
@NP	e.g.	53507
@NP	et al. , 1998	53522
@NP	et al.	53522
@NP	1998	53530
@NP	Jakeman	53536
@NP	et al. , 1998	53544
@NP	et al.	53544
@NP	1998	53552
@NP	von Meyenburg et al. , 1998	53558
@NP	von Meyenburg	53558
@NP	et al. , 1998	53572
@NP	et al.	53572
@NP	1998	53580
@NP	Tuszynski et al. , 1999	53586
@NP	Tuszynski	53586
@NP	et al. , 1999	53596
@NP	et al.	53596
@NP	1999	53604
@NP	Corbetta et al. , 2002	53610
@NP	Corbetta	53610
@NP	et al. , 2002	53619
@NP	et al.	53619
@NP	2002	53627
@NP	Gomez-Pinilla et al. , 2002	53633
@NP	Gomez-Pinilla	53633
@NP	et al. , 2002	53647
@NP	et al.	53647
@NP	2002	53655
@NP	Blits et al. , 2003	53661
@NP	Blits	53661
@NP	et al. , 2003	53667
@NP	et al.	53667
@NP	2003	53675
@NP	Ruitenberg et al. , 2003	53681
@NP	Ruitenberg	53681
@NP	et al. , 2003	53692
@NP	et al.	53692
@NP	2003	53700
@NP	Bareyre et al.	53706
@NP	Bareyre	53706
@NP	et al.	53714
@NP	2004	53722
@NP	mechanisms of action	53738
@NP	mechanisms	53738
@NP	action	53752
@NP	functional compensation	53767
@NP	pathways	53812
@NP	the stimulation of ` central pattern generators '	53822
@NP	the stimulation	53822
@NP	central pattern generators '	53842
@NP	pattern generators '	53850
@NP	simple motor programs	53871
@NP	the distal spinal cord	53901
@NP	plasticity	53937
@NP	the spinal cord or higher brain centres	53959
@NP	the spinal cord	53959
@NP	higher brain centres	53978
@NP	plasticity	54024
@NP	remaining tissue , surrounding a partial lesion	54049
@NP	remaining tissue	54049
@NP	a partial lesion	54079
@NP	the functional roles of the damaged motor tracts	54110
@NP	the functional roles	54110
@NP	the damaged motor tracts	54134
@NP	recovery of movement	54179
@NP	recovery	54179
@NP	movement	54191
@NP	our study	54204
@NP	the rubrospinal tract	54215
@NP	many functional similarities to the CST -LRB- Kennedy , 1990 -RRB-	54248
@NP	many functional similarities	54248
@NP	the CST	54280
@NP	Kennedy	54289
@NP	1990	54298
@NP	fine motor control -LRB- Whishaw et al. , 1990 -RRB-	54323
@NP	fine motor control	54323
@NP	Whishaw	54343
@NP	et al. , 1990	54351
@NP	et al.	54351
@NP	1990	54359
@NP	a role	54386
@NP	it	54400
@NP	the CST	54434
@NP	a study by Weidner et al. -LRB- 2001 -RRB-	54458
@NP	a study by Weidner et al.	54458
@NP	a study by Weidner	54458
@NP	a study	54458
@NP	Weidner	54469
@NP	et al.	54477
@NP	2001	54485
@NP	spontaneous	54500
@NP	the ventral CST	54525
@NP	ablation of the dorsal	54547
@NP	ablation	54547
@NP	the dorsal	54559
@NP	CST , which correlated with improvements in forelimb function	54570
@NP	CST	54570
@NP	improvements	54597
@NP	forelimb function	54613
@NP	we	54641
@NP	the ventral portion of the CST	54658
@NP	the ventral portion	54658
@NP	the CST	54681
@NP	a similar mechanism	54690
@NP	we	54752
@NP	functional improvements	54766
@NP	the extent	54817
@NP	anatomical regeneration and reconnection	54831
@NP	descending nerve tract circuitry within the injured rodent spinal cord	54875
@NP	descending nerve tract circuitry	54875
@NP	the injured rodent spinal cord	54915
@NP	Gene therapy combined with OEG transplantation	54947
@NP	Gene therapy	54947
@NP	OEG transplantation	54974
@NP	a significant effect on the maintenance/regeneration of CST fibres	54998
@NP	a significant effect	54998
@NP	the maintenance/regeneration of CST fibres	55022
@NP	the maintenance/regeneration	55022
@NP	CST fibres	55054
@NP	sparing of spinal cord tissue in general	55070
@NP	sparing	55070
@NP	spinal cord tissue in general	55081
@NP	spinal cord tissue	55081
@NP	general	55103
@NP	These results	55112
@NP	credence to further study of OEG	55131
@NP	credence	55131
@NP	further study of OEG	55143
@NP	further study	55143
@NP	OEG	55160
@NP	transplantation	55164
@NP	combination	55183
@NP	long-term secretion of neurotrophic factors , e.g.	55200
@NP	long-term secretion	55200
@NP	neurotrophic factors	55223
@NP	lentiviral vectors	55259
@NP	Ruitenberg	55279
@NP	et al. , 2002a	55290
@NP	et al.	55290
@NP	2002a	55298
@NP	There	55306
@NP	functional axonal regeneration , compensation and axonal plasticity	55367
@NP	potential outcomes	55437
@NP	spinal cord injuries	55462
@NP	Development of more appropriate measures of sensorimotor performance	55484
@NP	Development	55484
@NP	more appropriate measures of sensorimotor performance	55499
@NP	more appropriate measures	55499
@NP	sensorimotor performance	55528
@NP	rodents	55556
@NP	e.g.	55565
@NP	Metz and Whishaw	55570
@NP	2002	55588
@NP	better , more realistic and hopefully more clinically relevant interpretation	55605
@NP	functional outcomes	55685
@NP	spinal cord injury in these animals	55711
@NP	spinal cord injury	55711
@NP	these animals	55733
@VP	promotes spinal sparing and regeneration Marc J.	60
@VP	used to transduce olfactory ensheathing glia	356
@VP	to transduce olfactory ensheathing glia	361
@VP	transduce olfactory ensheathing glia	364
@VP	shown by in situ hybridization and enzyme-linked immunosorbent assay techniques	496
@VP	was determined in a dorsal root ganglia neurite outgrowth assay	624
@VP	determined in a dorsal root ganglia neurite outgrowth assay	628
@VP	Transplanted	857
@VP	transduced with AdV vectors encoding NT-3 or LacZ , respectively	945
@VP	encoding NT-3 or LacZ , respectively	973
@VP	compared with control -LRB- medium-injected -RRB- rats	1112
@VP	tracing of the lesioned CST projection	1170
@VP	originating from the contralateral sensorimotor cortex	1210
@VP	reaching task with Eshkol	1460
@VP	were occurring after OEG implantation	1695
@VP	occurring after OEG implantation	1700
@VP	per se can promote tissue sparing after injury	1783
@VP	promote tissue sparing after injury	1794
@VP	promoting long-distance maintenance/regeneration of lesioned adult CST axons	1935
@VP	to regenerate axons after injury	2078
@VP	regenerate axons after injury	2081
@VP	severed spinal cord axons	2617
@VP	could contribute to their growth-permissive properties	3060
@VP	contribute to their growth-permissive properties	3066
@VP	secreted by OEG	3132
@VP	is also produced in small amounts	3289
@VP	produced in small amounts	3297
@VP	continues to be expressed after injury -LRB- Liebl et al. , 2001 -RRB-	3845
@VP	to be expressed after injury -LRB- Liebl et al. , 2001 -RRB-	3855
@VP	be expressed after injury -LRB- Liebl et al. , 2001 -RRB-	3858
@VP	expressed after injury -LRB- Liebl et al. , 2001 -RRB-	3861
@VP	appears to be a critical factor in CST growth and plasticity	3930
@VP	to be a critical factor in CST growth and plasticity	3938
@VP	be a critical factor in CST growth and plasticity	3941
@VP	can result in a cell type that is more effective in promoting spinal cord repair	4108
@VP	result in a cell type that is more effective in promoting spinal cord repair	4112
@VP	is more effective in promoting spinal cord repair	4139
@VP	promoting spinal cord repair	4160
@VP	providing an environment more conducive to CST regrowth after injury	4343
@VP	visualizing both left and right CST projections	4688
@VP	resulting from such an injury	5310
@VP	were approved by The University of Western Australia Animal Ethics Committee	5454
@VP	approved by The University of Western Australia Animal Ethics Committee	5459
@VP	administering measured amounts of food each day	5585
@VP	measured amounts of food each day	5599
@VP	to perform the food pellet retrieval task -LRB- Whishaw and Pellis , 1990 -RRB-	5708
@VP	perform the food pellet retrieval task -LRB- Whishaw and Pellis , 1990 -RRB-	5711
@VP	were trained for behaviour analysis for 2 weeks prior to surgery	5797
@VP	trained for behaviour analysis for 2 weeks prior to surgery	5802
@VP	were unable to learn the task and were excluded from the experiment	5867
@VP	were unable to learn the task	5867
@VP	to learn the task	5879
@VP	learn the task	5882
@VP	were excluded from the experiment	5901
@VP	excluded from the experiment	5906
@VP	underwent surgery at the end of the pre-training period	5961
@VP	were allowed 2 weeks recovery before post-injury behavioural testing	6021
@VP	allowed 2 weeks recovery before post-injury behavioural testing	6026
@VP	using the forelimb reaching task	6121
@VP	reaching task	6140
@VP	were sacrificed for histological analysis	6237
@VP	sacrificed for histological analysis	6242
@VP	described in Plant et al. -LRB- 2003 -RRB-	6427
@VP	dissected away from the ventral part of the olfactory bulbs	6501
@VP	diced into small pieces	6562
@VP	buffered salt solution -LRB- HBSS ; Sigma , USA -RRB- for 60 min at 37 °C	6696
@VP	was then triturated until a single cell suspension was obtained	6769
@VP	triturated until a single cell suspension was obtained	6778
@VP	was obtained	6820
@VP	obtained	6824
@VP	harvested by low-speed centrifugation , re-suspended	6845
@VP	plated onto poly-L-lysine - -LRB- PLL ; Sigma -RRB- coated dishes	6901
@VP	was replaced after 3	6967
@VP	replaced after 3	6971
@VP	have been described elsewhere -LRB- Ruitenberg et al. , 2002a -RRB-	7291
@VP	been described elsewhere -LRB- Ruitenberg et al. , 2002a -RRB-	7296
@VP	described elsewhere -LRB- Ruitenberg et al. , 2002a -RRB-	7301
@VP	encoding either LacZ or NT-3	7385
@VP	added to the culture medium	7508
@VP	incubated with the cells overnight in a 37 °C tissue culture incubator	7540
@VP	was replaced with fresh medium	7645
@VP	replaced with fresh medium	7649
@VP	left for 48 h to allow initiation of transgene expression	7690
@VP	to allow initiation of transgene expression	7704
@VP	allow initiation of transgene expression	7707
@VP	stained for expression of the LacZ gene using X-gal histochemistry	7789
@VP	using X-gal histochemistry	7829
@VP	examined for NT-3 mRNA expression using standard non-radioactive in situ	7859
@VP	using standard non-radioactive in situ	7893
@VP	was confirmed in vitro prior to transplantation	8019
@VP	confirmed in vitro prior to transplantation	8023
@VP	secreted NT-3	8498
@VP	was expressed as ng of NT-3 derived from a transduced culture per day	8512
@VP	expressed as ng of NT-3 derived from a transduced culture per day	8516
@VP	derived from a transduced culture per day	8540
@VP	transduced culture per day	8555
@VP	were grown for 48 h in the presence of conditioned medium from OEG cultures	8809
@VP	grown for 48 h in the presence of conditioned medium from OEG cultures	8814
@VP	infected with AdV-NT - 3 , AdV-LacZ or no virus , respectively	8885
@VP	subjected to standard in situ hybridization using digoxygenin -LRB- DIG -RRB-	9419
@VP	in situ hybridization using digoxygenin -LRB- DIG -RRB-	9441
@VP	transduced OEG The purity of OEG cultures used for transplantation	9591
@VP	used for transplantation	9633
@VP	was confirmed by immunocytochemistry for antigenic OEG markers	9658
@VP	confirmed by immunocytochemistry for antigenic OEG markers	9662
@VP	conjugated goat anti-rabbit IgG -LRB- Vector Laboratories Inc. , USA -RRB-	9913
@VP	stain ; Hoechst 33342 dye	10296
@VP	stain	10296
@VP	dye	10317
@VP	had a mitogenic effect on adult OEG derived from the olfactory bulb nerve layer	10368
@VP	derived from the olfactory bulb nerve layer	10404
@VP	Purified OEG	10548
@VP	described above	10578
@VP	modified Eagle 's medium -LRB- DMEM ; Sigma -RRB-	10696
@VP	supplemented with 10 % fetal bovine serum -LRB- DF-10S -RRB- plus mitogens	10775
@VP	was replaced with either serum-free chemically defined -LRB- CD -RRB-	10935
@VP	replaced with either serum-free chemically defined -LRB- CD -RRB-	10939
@VP	chemically defined	10971
@VP	were left for 48 h.	11072
@VP	left for 48 h.	11077
@VP	growing in CD medium	11112
@VP	described above	11207
@VP	were fed daily with new medium containing freshly thawed NT-3	11490
@VP	fed daily with new medium containing freshly thawed NT-3	11495
@VP	containing freshly	11521
@VP	thawed NT-3	11540
@VP	were pulsed with 10 µM BrdU and incubated for 24 h prior to fixation	11608
@VP	incubated for 24 h prior to fixation	11640
@VP	dividing cells under the different experimental conditions	11696
@VP	to identify OEG	11911
@VP	identify OEG	11914
@VP	were taken of five random fields across each coverslip for cell counts	11977
@VP	taken of five random fields across each coverslip for cell counts	11982
@VP	was repeated twice	12195
@VP	repeated twice	12199
@VP	using E15 DRG explants	12510
@VP	prepared as described above	12534
@VP	described above	12546
@VP	were grown in NeurobasalTM medium -LRB- Gibco -RRB- for 72 h.	12581
@VP	grown in NeurobasalTM medium -LRB- Gibco -RRB- for 72 h.	12586
@VP	were then triple stained with nuclear Hoechst dye	12650
@VP	triple stained with nuclear Hoechst dye	12660
@VP	dye	12696
@VP	using standard immunohistochemical techniques	12780
@VP	were described previously -LRB- Ruitenberg et al. , 2002a , b -RRB-	12914
@VP	described previously -LRB- Ruitenberg et al. , 2002a , b -RRB-	12919
@VP	operated rats	12980
@VP	received injections of OEG-NT-3 in a 1	13001
@VP	were injected with OEG-LacZ	13076
@VP	injected with OEG-LacZ	13081
@VP	received non-modified OEG	13111
@VP	were injected with vehicle alone	13153
@VP	injected with vehicle alone	13158
@VP	did not recover from the surgery	13196
@VP	recover from the surgery	13204
@VP	continued to lose weight , reacting adversely to the injury ,	13248
@VP	to lose weight , reacting adversely to the injury ,	13258
@VP	lose weight , reacting adversely to the injury ,	13261
@VP	reacting adversely to the injury	13274
@VP	consequently was sacrificed during the first postoperative week	13312
@VP	sacrificed during the first postoperative week	13329
@VP	were used for post-lesion analysis of behaviour	13393
@VP	used for post-lesion analysis of behaviour	13398
@VP	test for NT-3 mRNA expression in OEG transplants in vivo -LRB- see above -RRB-	13480
@VP	see above	13538
@VP	made in the skin covering the cervical neck region , and the underlying shoulder	13727
@VP	covering the cervical neck region	13744
@VP	were separated using forceps	13824
@VP	separated using forceps	13829
@VP	using forceps	13839
@VP	was performed	13885
@VP	performed	13889
@VP	was carefully cut to expose the spinal cord	13912
@VP	cut to expose the spinal cord	13926
@VP	to expose the spinal cord	13930
@VP	expose the spinal cord	13933
@VP	aimed to transect the dorsal hemisphere completely including the CST	14097
@VP	to transect the dorsal hemisphere completely including the CST	14103
@VP	transect the dorsal hemisphere completely including the CST	14106
@VP	containing 100 000 cells	14330
@VP	were prepared as originally described in Ruitenberg et al. -LRB- 2002a -RRB-	14457
@VP	prepared as originally described in Ruitenberg et al. -LRB- 2002a -RRB-	14462
@VP	described in Ruitenberg et al. -LRB- 2002a -RRB-	14485
@VP	performing spinal surgery and OEG implantation	14540
@VP	was unaware of transplant conditions	14587
@VP	to place theOEGwithin the dorsalCSTprojection area	14760
@VP	place theOEGwithin the dorsalCSTprojection area	14763
@VP	was made 1 mm proximal to the lesion and the second 1 mm distal to the lesion	14832
@VP	made 1 mm proximal to the lesion and the second 1 mm distal to the lesion	14836
@VP	were then sutured together	14927
@VP	sutured together	14937
@VP	was closed with Michel surgical clips -LRB- Fine Science Tools , Canada -RRB-	14967
@VP	closed with Michel surgical clips -LRB- Fine Science Tools , Canada -RRB-	14971
@VP	blinded to the experimental treatment	15538
@VP	Forelimb reaching task and movement analysis	15662
@VP	to place food pellets	15841
@VP	place food pellets	15844
@VP	see Fig. 2	15864
@VP	consisted of a metal grating	15898
@VP	grating	15919
@VP	dropped food pellets could not be retrieved	15937
@VP	could not be retrieved	15958
@VP	be retrieved	15968
@VP	retrieved	15971
@VP	were small enough for the rats to grasp easily and appeared an attractive reward	16064
@VP	were small enough for the rats to grasp easily	16064
@VP	to grasp easily	16095
@VP	grasp easily	16098
@VP	appeared an attractive reward	16115
@VP	to encourage the animals to reach with the right forelimb	16237
@VP	encourage the animals to reach with the right forelimb	16240
@VP	to reach with the right forelimb	16262
@VP	reach with the right forelimb	16265
@VP	replaced with another irrespective of whether it was eaten or dropped	16324
@VP	was eaten or dropped	16373
@VP	eaten or dropped	16377
@VP	reached through the opening	16436
@VP	grabbed the food pellet with its right paw	16465
@VP	transferred it to its mouth	16512
@VP	were not scored	16583
@VP	scored	16592
@VP	was made if the food pellet was dropped inside the test box	16622
@VP	made if the food pellet was dropped inside the test box	16626
@VP	was dropped inside the test box	16650
@VP	dropped inside the test box	16654
@VP	was incidentally knocked off the shelf outside the test box	16702
@VP	knocked off the shelf outside the test box	16719
@VP	was not scored	16768
@VP	scored	16776
@VP	was replaced	16798
@VP	replaced	16802
@VP	performed in 2 min	16883
@VP	were calculated from three independent measurements over a 7 day period	16903
@VP	calculated from three independent measurements over a 7 day period	16908
@VP	involved in the forelimb reaching task	17006
@VP	reaching task	17031
@VP	involved in forelimb reaching	17281
@VP	reaching	17302
@VP	tracing Following the conclusion of behavioural experiments	17403
@VP	was made through the skin covering the skull	17571
@VP	made through the skin covering the skull	17575
@VP	covering the skull	17597
@VP	elongated craniotomies	17621
@VP	made at 5 mm either side of the midline from -7.1 mm bregma to + 2.9 mm lambda	17649
@VP	biotinylated dextran amine	17748
@VP	using a Hamilton syringe	17934
@VP	conjugated with Texas red	17964
@VP	conjugated with fluorescein	18094
@VP	was injected into the left cortex , contralateral to the lesion site	18130
@VP	injected into the left cortex , contralateral to the lesion site	18134
@VP	were dissected from each animal and post-fixed for 24 h.	18608
@VP	dissected from each animal and post-fixed for 24 h.	18613
@VP	dissected from each animal	18613
@VP	post-fixed for 24 h.	18644
@VP	were extracted from the skull and vertebra	18691
@VP	extracted from the skull and vertebra	18696
@VP	stored intact in 0.1 M phosphate buffer -LRB- PB , pH 7.4 -RRB-	18738
@VP	to confirm that all animals were lesioned at the same level	18890
@VP	confirm that all animals were lesioned at the same level	18893
@VP	were lesioned at the same level	18918
@VP	lesioned at the same level	18923
@VP	cut from the spinal cord , with the lesion at the mid-point of this segment	18970
@VP	embedded in gelatine	19050
@VP	containing 0.1 M PB with 0.01 % sodium azide -LRB- Sigma -RRB-	19273
@VP	stored at 4 °C until processed for immunohistochemistry	19330
@VP	processed for immunohistochemistry	19350
@VP	cortically injected animals	19417
@VP	were successfully labelled with BDA tracer	19445
@VP	labelled with BDA tracer	19463
@VP	remaining BDA-G-labelled fibres present in and beyond the damaged area	19637
@VP	concentrated in one area	19723
@VP	were seen throughout the distal grey matter of the spinal cord segment	19872
@VP	seen throughout the distal grey matter of the spinal cord segment	19877
@VP	was excluded from further histological analysis	19956
@VP	excluded from further histological analysis	19960
@VP	was assigned the number 1	20062
@VP	assigned the number 1	20066
@VP	being the lateral right-most part of the spinal cord	20094
@VP	were collected per spinal cord	20174
@VP	collected per spinal cord	20179
@VP	was immunostained for GFAP , visualizing reactive astrocytes in the lesion area	20248
@VP	immunostained for GFAP , visualizing reactive astrocytes in the lesion area	20252
@VP	visualizing reactive astrocytes in the lesion area	20276
@VP	were used to visualize labelled cells	20586
@VP	used to visualize labelled cells	20591
@VP	to visualize labelled cells	20596
@VP	visualize labelled cells	20599
@VP	were described previously -LRB- Ruitenberg et al. , 2002a , 2003 -RRB-	20717
@VP	described previously -LRB- Ruitenberg et al. , 2002a , 2003 -RRB-	20722
@VP	attached to a Nikon Optiphot-2 microscope	20996
@VP	were based on the level of fluorescence in each section	21135
@VP	based on the level of fluorescence in each section	21140
@VP	was excluded by altering the intensity thresholds	21321
@VP	excluded by altering the intensity thresholds	21325
@VP	altering the intensity thresholds	21337
@VP	could not entirely exclude all background signal from each image	21876
@VP	exclude all background signal from each image	21895
@VP	To control for this	21942
@VP	control for this	21945
@VP	used to correct signal fluorescence at the four distances across the lesion site	22131
@VP	to correct signal fluorescence at the four distances across the lesion site	22136
@VP	correct signal fluorescence at the four distances across the lesion site	22139
@VP	defined the labelled and non-labelled areas	22554
@VP	to obtain a percentage label	22689
@VP	obtain a percentage label	22692
@VP	was subtracted from the final value as described earlier	22743
@VP	subtracted from the final value as described earlier	22747
@VP	described earlier	22782
@VP	sparing Every fourth sagittal section from the spinal cord	22829
@VP	used to determine the volume of spared tissue -LRB- Plant et al. , 2003 -RRB-	22892
@VP	to determine the volume of spared tissue -LRB- Plant et al. , 2003 -RRB-	22897
@VP	determine the volume of spared tissue -LRB- Plant et al. , 2003 -RRB-	22900
@VP	was measured	23246
@VP	measured	23250
@VP	contained the grafted cells and usually some small cysts	23471
@VP	were summed per rat and corrected for the total number of sections	23560
@VP	summed per rat and corrected for the total number of sections	23565
@VP	summed per rat	23565
@VP	corrected for the total number of sections	23584
@VP	Spared spinal tissue	23628
@VP	to estimate graft size , using p75-stained sections	23852
@VP	estimate graft size , using p75-stained sections	23855
@VP	using p75-stained sections	23876
@VP	shows means 6 SD to better visualize intra-group variation	24540
@VP	means 6 SD to better visualize intra-group variation	24546
@VP	to better visualize intra-group variation	24557
@VP	better visualize intra-group variation	24560
@VP	cultured cells	24791
@VP	expressed the LacZ gene product	24806
@VP	transduced with AdV-NT-3 vector	24892
@VP	expressed high levels of this neurotrophin after 72 h in vitro	24924
@VP	was visually inspected after 48 h.	25128
@VP	inspected after 48 h.	25141
@VP	cultured DRG explants	25301
@VP	showing neurite extensions with growth cone-like structures	25375
@VP	taken from control	25459
@VP	induced very little outgrowth from DRG explants	25498
@VP	were normal in experimental rats	25895
@VP	were capable of targeted reaching through the opening with their right forepaw	25941
@VP	targeted reaching through the opening with their right forepaw	25957
@VP	reaching through the opening with their right forepaw	25966
@VP	grabbed the food pellet and , subsequently , transferred it to their mouth	26026
@VP	grabbed the food pellet	26026
@VP	transferred it to their mouth	26069
@VP	was paralysed	26224
@VP	paralysed	26228
@VP	making the skilled reaches that are required to grab the food pellet reward	26271
@VP	are required to grab the food pellet reward	26303
@VP	required to grab the food pellet reward	26307
@VP	to grab the food pellet reward	26316
@VP	grab the food pellet reward	26319
@VP	had significantly improved among all experimental groups	26411
@VP	improved among all experimental groups	26429
@VP	was raised in the air	26759
@VP	raised in the air	26763
@VP	was then pronated over the food pellet	26795
@VP	pronated over the food pellet	26804
@VP	retracted back to drag it into the animals mouth as illustrated	26847
@VP	to drag it into the animals mouth as illustrated	26862
@VP	drag it into the animals mouth as illustrated	26865
@VP	were virtually absent	26961
@VP	lesioning	27121
@VP	Note the -LRB- spontaneous -RRB- improvement	27162
@VP	was observed over time in all groups	27202
@VP	observed over time in all groups	27206
@VP	analysed	27362
@VP	Note that animal 11	27513
@VP	was observed in animal 18	27682
@VP	observed in animal 18	27686
@VP	showing the two	28045
@VP	labelled CST projections in an uninjured control animal	28074
@VP	showing the dorsal column region and labelled CST projections	28193
@VP	showing the dorsal column region	28193
@VP	labelled CST projections	28230
@VP	Note the distinct labelling of axons within both CST projections	28256
@VP	were seen in the BDA-R-labelled CST , and vice versa	28360
@VP	seen in the BDA-R-labelled CST , and vice versa	28365
@VP	seen in the BDA-R-labelled CST	28365
@VP	vice versa	28401
@VP	showing successfully	28513
@VP	was still intact	28599
@VP	had developed enlarged , bulbous ends	28636
@VP	developed enlarged , bulbous ends	28640
@VP	were seen to collect at the rostral edge of the lesion site	28697
@VP	seen to collect at the rostral edge of the lesion site	28702
@VP	to collect at the rostral edge of the lesion site	28707
@VP	collect at the rostral edge of the lesion site	28710
@VP	was induced in animals receiving control -LRB- OEG and OEG-LacZ -RRB- implants	28802
@VP	induced in animals receiving control -LRB- OEG and OEG-LacZ -RRB- implants	28806
@VP	receiving control -LRB- OEG and OEG-LacZ -RRB- implants	28825
@VP	surrounding the lesion and implantation site	28941
@VP	enriched in p75-positive -LRB- red -RRB- cells and between 95 and 98 % pure as	29253
@VP	Cultured OEG	29429
@VP	were also immunoreactive for GFAP -LRB- green -RRB-	29442
@VP	as observed in OEG-transplanted animals only	29614
@VP	bypassing the lesion area through the more ventral portions	29838
@VP	were detected at least up to 1 cm distally	29903
@VP	detected at least up to 1 cm distally	29908
@VP	outlined by the dashed line	30010
@VP	entering the ventral portions of the damaged area	30142
@VP	extending into the opposing part of the spinal cord	30196
@VP	taken from an OEG-LacZ-transplanted rat at 12 weeks after surgery	30320
@VP	dashed line	30581
@VP	demonstrating the completeness of the injury	30595
@VP	Scattered BDA-G-labelled fibres	30645
@VP	seen at 1 cm distal to the injury site in OEG-NT-3-transplanted animals only	30682
@VP	to quantify fibre fluorescence using image analysis software	31219
@VP	quantify fibre fluorescence using image analysis software	31222
@VP	using image analysis software	31250
@VP	signifies the regions of analysis	31315
@VP	obtained from sagittal spinal cord sections from all experimental groups	31414
@VP	presented as pixels of fluorescence	31491
@VP	tracing -LRB- relative percentage of fluorescence intensity ± SEM -RRB-	31965
@VP	reduce the spinal cord lesion size and preserve tissue	32203
@VP	reduce the spinal cord lesion size	32203
@VP	preserve tissue	32242
@VP	were seen between the different experimental groups	32529
@VP	seen between the different experimental groups	32534
@VP	was significantly smaller in all OEG-implanted animals and even further	32616
@VP	was significantly larger in OEGand OEG-LacZ-transplanted rats	32807
@VP	purified adult OEG	33239
@VP	purified adult OEG	33286
@VP	dye	33498
@VP	dye results in a purple nuclear stain	33589
@VP	stain	33621
@VP	grown in CD - or DF-10S medium , containing various amounts of NT-3 ,	33704
@VP	containing various amounts of NT-3	33735
@VP	transduced with AdV-NT-3	33774
@VP	expected	33803
@VP	was much lower in medium , containing no serum , pituitary extract and forskolin	33851
@VP	containing no serum , pituitary extract and forskolin	33877
@VP	transduced cells or added as recombinant protein to the culture medium	33984
@VP	transduced cells	33984
@VP	added as recombinant protein to the culture medium	34004
@VP	had a mitogenic effect on OEG -LRB- P > 0.05 -RRB-	34056
@VP	-LRB- immuno - -RRB- stained	34191
@VP	dye	34271
@VP	stain	34289
@VP	was observed	34374
@VP	observed	34378
@VP	expected	34395
@VP	induced robust , radial fibre outgrowth from the explant	34455
@VP	Note the increased dispersal of Schwann cells in the presence of NT-3	34512
@VP	transduced with first generation E1-deleted AdV vectors encoding LacZ or NT-3	34709
@VP	encoding LacZ or NT-3	34765
@VP	were seen in vitro	34852
@VP	seen in vitro	34857
@VP	were labelled 3 days after infection	34890
@VP	labelled 3 days after infection	34895
@VP	displayed similar morphology to control OEG cultures	34945
@VP	to control OEG cultures	34974
@VP	control OEG cultures	34977
@VP	appeared absent	35012
@VP	showed no expression of either LacZ or NT-3 -LRB- not shown -RRB-	35049
@VP	not shown	35094
@VP	using standard ELISA	35181
@VP	produced net NT-3 levels of 40 ± 7.4 ng/10 ^ 5 cells/24 h.	35277
@VP	h.	35331
@VP	could not be detected in non-transduced and OEGLacZ cultures	35347
@VP	be detected in non-transduced and OEGLacZ cultures	35357
@VP	detected in non-transduced and OEGLacZ cultures	35360
@VP	grown in supernatant from OEGNT - 3 cultures -LRB- Fig. 1C and D -RRB-	35661
@VP	grown in conditioned medium from either non-transduced OEG or OEGLacZ cultures	35792
@VP	labelled cells of bipolar OEG morphology	36072
@VP	were detected in the transplantation area	36113
@VP	detected in the transplantation area	36118
@VP	was present in animals that received injections with OEG-LacZ or ` medium only	36173
@VP	received injections with OEG-LacZ or ` medium only	36201
@VP	documented previously -LRB- Ruitenberg et al. , 2003 -RRB-	36256
@VP	focused p75 labelling in adjacent immunoreacted spinal cord sections	36305
@VP	was co-extensive with regions containing intense NT-3 mRNA expression	36374
@VP	containing intense NT-3 mRNA expression	36404
@VP	was frequently to constantly weight supported with plantar steps	36683
@VP	to constantly weight supported with plantar steps	36698
@VP	weight supported with plantar steps	36712
@VP	supported with plantar steps	36719
@VP	was only occasional coordination between fore - and hindlimbs	36758
@VP	was scored for all animals from week 4 onwards	36842
@VP	scored for all animals from week 4 onwards	36846
@VP	had difficulties in raising the right forelimb	37023
@VP	raising the right forelimb	37043
@VP	was raised in the air	37170
@VP	raised in the air	37174
@VP	was then pronated over the food pellet	37205
@VP	pronated over the food pellet	37214
@VP	to drag it towards the inner edge of the shelf as illustrated in Fig. 2A	37272
@VP	drag it towards the inner edge of the shelf as illustrated in Fig. 2A	37275
@VP	illustrated in Fig. 2A	37322
@VP	were virtually absent	37395
@VP	eaten in 2 min	37471
@VP	eaten in 2 min ; see Fig. 2B	37700
@VP	see Fig. 2B	37716
@VP	had improved across all groups -LRB- 9 -- 25 pellets / 2 min -RRB-	37828
@VP	improved across all groups -LRB- 9 -- 25 pellets / 2 min -RRB-	37832
@VP	were scored between 0 and 2 , indicating normal forelimb performance	38115
@VP	scored between 0 and 2 , indicating normal forelimb performance	38120
@VP	indicating normal forelimb performance	38144
@VP	exemplified by animal no. 18 ; Fig. 2D , left panel	38805
@VP	left panel	38844
@VP	remained relatively constant while pellet retrieval continued to improve	39175
@VP	continued to improve	39227
@VP	to improve	39237
@VP	improve	39240
@VP	tracing Both dorso-medial CST projections	39287
@VP	see diagram , Fig. 3A	39386
@VP	were used to optimize the tracing procedure -LRB- Fig. 3B and C -RRB-	39452
@VP	used to optimize the tracing procedure -LRB- Fig. 3B and C -RRB-	39457
@VP	to optimize the tracing procedure -LRB- Fig. 3B and C -RRB-	39462
@VP	optimize the tracing procedure -LRB- Fig. 3B and C -RRB-	39465
@VP	were observed ipsilateral to the injected cortical hemisphere	39613
@VP	observed ipsilateral to the injected cortical hemisphere	39618
@VP	were labelled as described above	39716
@VP	labelled as described above	39721
@VP	described above	39733
@VP	were obtained per rat , 8 -- 10 of which contained BDA-G-labelled fibres	39798
@VP	obtained per rat , 8 -- 10 of which contained BDA-G-labelled fibres	39803
@VP	contained BDA-G-labelled fibres	39835
@VP	operated rats	39875
@VP	to appear wider here than in more proximal undamaged parts	40021
@VP	appear wider here than in more proximal undamaged parts	40024
@VP	abutting the proximal border of the glial scar	40427
@VP	extracted from the olfactory bulbs of adult Fischer 344 rats	40570
@VP	were examined prior to transplantation	40632
@VP	examined prior to transplantation	40637
@VP	Cultured OEG	40672
@VP	not shown	40715
@VP	used for transplantation purposes	40778
@VP	calculated from the ratio of p75-stained cells to the total cell number	40839
@VP	seen within the damaged area of all OEG-transplanted animals -LRB- Fig. 4B -RRB-	40968
@VP	had entered the injured cord -LRB- Ruitenberg et al. , 2003 -RRB-	41096
@VP	entered the injured cord -LRB- Ruitenberg et al. , 2003 -RRB-	41100
@VP	were found in vehicle-injected controls	41152
@VP	found in vehicle-injected controls	41157
@VP	out of the five animals analysed receiving OEG-NT-3 implants	41210
@VP	receiving OEG-NT-3 implants	41243
@VP	were scattered in distribution	41483
@VP	scattered in distribution	41488
@VP	had a beaded appearance and uneven trajectory -LRB- Fig. 4D -RRB-	41515
@VP	being characteristic of regeneratingCSTfibres -LRB- Steward et al. , 2003 -RRB-	41593
@VP	see later	42047
@VP	was the maximum distance measured	42065
@VP	measured	42090
@VP	labelled axons	42106
@VP	showing consistently higher signal fluorescence in the lesion centre	42934
@VP	was approximated at both + 0.5 mm -LRB- P = 0.085 -RRB-	43206
@VP	approximated at both + 0.5 mm -LRB- P = 0.085 -RRB-	43210
@VP	compared with its control , the OEG-LacZ group	43282
@VP	labelled projections at 1 cm distal to the injury	43430
@VP	measured 1 cm proximal to the injury	43526
@VP	found for the OEG - -LRB- 1.5 ± 0.7 % ; n = 5 -RRB- and OEG-LacZ	43749
@VP	-LRB- 1.1 ± 0.2 % ; n = 5 -RRB- transplanted	43802
@VP	were seen 1 cm below the injury site -LRB- 9.1 ± 1.43 % ; n = 5 ; Fig. 5D -RRB-	43937
@VP	seen 1 cm below the injury site -LRB- 9.1 ± 1.43 % ; n = 5 ; Fig. 5D -RRB-	43942
@VP	-RSB-	44141
@VP	received vehicle injections , OEG or OEG-LacZ transplants	44215
@VP	was significantly greater compared with other groups -LRB- P < 0.0005 -RRB-	44342
@VP	sparing Spinal tissue sparing	44617
@VP	examined	44884
@VP	was spared	44893
@VP	spared	44897
@VP	was spared in OEG - -LRB- 87.7 ± 1.0 % ; n = 5 -RRB- , OEG-LacZ	44963
@VP	spared in OEG - -LRB- 87.7 ± 1.0 % ; n = 5 -RRB- , OEG-LacZ	44967
@VP	implanted groups	45070
@VP	were similar between experimental groups -LRB- P > 0.05 ; Fig. 6B -RRB-	45114
@VP	decreased in all transplanted animals -LRB- P < 0.004 ; Fig. 6C -RRB-	45226
@VP	expected	45289
@VP	virally encoded	45936
@VP	were grown in	46010
@VP	grown in	46015
@VP	were obtained from the olfactory bulb nerve layer	46207
@VP	obtained from the olfactory bulb nerve layer	46212
@VP	adding recombinant NT-3 to OEG cultures	46282
@VP	not shown	46565
@VP	to confirm biological activity of this recombinant neurotrophin	46647
@VP	confirm biological activity of this recombinant neurotrophin	46650
@VP	increased Schwann cell dispersal from the explants -LRB- Fig. 7C and D -RRB-	46780
@VP	report the effects of genetically	46989
@VP	spared in all OEG-transplanted animals compared with vehicle-injected controls	47182
@VP	revealed some post-lesion recovery	47522
@VP	were no significant differences between experimental groups	47567
@VP	point to compensatory involvement of intraspinal circuitry	47763
@VP	other descending supraspinal pathways in post-lesion recovery	47829
@VP	descending supraspinal pathways	47835
@VP	could contribute to functional adaptation after the injury	48164
@VP	contribute to functional adaptation after the injury	48170
@VP	were p75 positive	48531
@VP	formed enlarged bulbous ends along the proximal edge of the lesion	49304
@VP	received vehicle injections or control implants	49385
@VP	represent true differences in outcomes	49750
@VP	transplant purity	49905
@VP	was there evidence of CST sprouting 0.5 and 1 mm distal to the lesion epicentre	49959
@VP	there evidence of CST sprouting 0.5 and 1 mm distal to the lesion epicentre	49963
@VP	sprouting 0.5 and 1 mm distal to the lesion epicentre	49985
@VP	were detected up to 1 cm distal to the lesion in the OEG-NT-3 group	50228
@VP	detected up to 1 cm distal to the lesion in the OEG-NT-3 group	50233
@VP	had a beaded appearance -LRB- Li et al. , 1997 -RRB-	50309
@VP	denervated spinal cord	50632
@VP	are used to discriminate true axonal regeneration from sparing	50803
@VP	used to discriminate true axonal regeneration from sparing	50807
@VP	to discriminate true axonal regeneration from sparing	50812
@VP	discriminate true axonal regeneration from sparing	50815
@VP	sparing	50858
@VP	remain an important area of debate	50924
@VP	was not due to a difference in overall tissue sparing	51143
@VP	released from	51297
@VP	were tested for skilled forelimb reaching	51457
@VP	tested for skilled forelimb reaching	51462
@VP	reaching	51490
@VP	showed severe impairment immediately after injury followed by partial recovery	51505
@VP	followed by partial recovery	51555
@VP	combined methylprednisolone administration with OEG transplantation	51757
@VP	remained relatively constant over the testing period	52031
@VP	did not differ between the experimental groups	52088
@VP	differ between the experimental groups	52096
@VP	indicates increasing success in the forelimb reaching task over time	52141
@VP	reaching task over time	52186
@VP	to reach for the food pellets	52261
@VP	reach for the food pellets	52264
@VP	revealed that specific task components were impaired by unilateral CST lesions	52583
@VP	were impaired by unilateral CST lesions	52622
@VP	impaired by unilateral CST lesions	52627
@VP	included supination , grasping and release of the food pellet	52669
@VP	grasping and release of the food pellet	52690
@VP	include the CST	52856
@VP	involving behavioural analysis	53020
@VP	are affected from damage to specific spinal motor pathways	53092
@VP	affected from damage to specific spinal motor pathways	53096
@VP	may have been more sensitive to a CST lesion in rats	53186
@VP	have been more sensitive to a CST lesion in rats	53190
@VP	been more sensitive to a CST lesion in rats	53195
@VP	be one requiring supination , grasping and release of the forepaw -LRB- e.g.	53245
@VP	requiring supination , grasping	53252
@VP	requiring supination	53252
@VP	grasping	53274
@VP	to contribute to functional recovery after spinal cord injury -LRB- e.g.	53444
@VP	contribute to functional recovery after spinal cord injury -LRB- e.g.	53447
@VP	Proposed mechanisms of action	53729
@VP	include functional compensation from related	53759
@VP	induced plasticity locally in the spinal cord or higher brain centres	53929
@VP	may allow for remaining tissue , surrounding a partial lesion	54035
@VP	allow for remaining tissue , surrounding a partial lesion	54039
@VP	surrounding a partial lesion	54067
@VP	take over the functional roles of the damaged motor tracts	54100
@VP	lead to recovery of movement	54171
@VP	has many functional similarities to the CST -LRB- Kennedy , 1990 -RRB-	54244
@VP	is involved in fine motor control -LRB- Whishaw et al. , 1990 -RRB-	54308
@VP	involved in fine motor control -LRB- Whishaw et al. , 1990 -RRB-	54311
@VP	is unlikely to play a role due to it also being lesioned along with the CST	54366
@VP	to play a role due to it also being lesioned along with the CST	54378
@VP	play a role due to it also being lesioned along with the CST	54381
@VP	being lesioned along with the CST	54408
@VP	lesioned along with the CST	54414
@VP	sprouting of the ventral CST after ablation of the dorsal	54512
@VP	correlated with improvements in forelimb function	54581
@VP	did not study the ventral portion of the CST	54644
@VP	study the ventral portion of the CST	54652
@VP	could have operated here	54710
@VP	have operated here	54716
@VP	operated here	54721
@VP	Taken together	54736
@VP	using lentiviral vectors	55253
